PLATELET CONCENTRATE AND TISSUE REGENERATION: DOES IT WORK? A PRE-CLINICAL STUDY by C. Ceci
  
UNIVERSITÀ DEGLI STUDI DI MILANO 
 
Scuola di Dottorato in 
Scienze Fisiopatologiche, Neuropsicobiologiche e Assistenziali del Ciclo 
della Vita 
Ciclo XXVIII 
Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche 
MED/28 
 
 
Platelet concentrate and tissue regeneration: 
does it work? A pre-clinical study 
 
 
 
Tutor: 
Chiar.mo Prof. Massimo DEL FABBRO 
Direttore della Scuola di Dottorato: 
Chiar.mo Prof. Roberto WEINSTEIN  
 
                                             Tesi di Dottorato di: 
Caterina CECI 
Matricola n. R09962 
 
 
 
Anno Accademico 2014 / 2015   
Table of contents 
 
1 
 
Table of contents 
 
TABLE OF CONTENTS 1-2 
ABSTRACT 3-4 
INTRODUCTION 5-38 
   1.  Platelets 5-14 
 1.1.  Megakaryocyte development 5-6 
 1.2.  Platelet formation 6-7 
 1.3.  Platelet structure 7-10 
 1.4.  Platelet functional role in hemostasis 10-13 
 1.5.  Platelet functional role in wound healing 13-14 
   2.  Platelet growth factors 14-22 
 2.1.  α Granules growth factors 16-19 
 2.2.  Growth factors biologic effects 20-22 
   3.  Platelet concentrates 22-31 
 3.1.  History of the medical use of platelet concentrates 22-27 
 3.2.  Classification 28 
 3.3.  Clinical and therapeutic applications 29-31 
   4.  Tissue engineering 31-38 
 4.1.  Essential components 33-36 
 4.2.  Mesenchymal stem cells 36-38 
AIM 39 
MATERIAL AND METHODS 40-51 
   1.  In vitro study 40-48 
 1.1.  Tissues 40 
Table of contents 
 
2 
 
 1.2.  Isolation and culture of cells 40-45 
 
1.3.  Blood collection and preparation of the activated 
        platelet concentrate 
45-46 
 1.4.  Cell proliferation assay 47 
 1.5.  Cell viability assay 47 
 1.6.  hASC and hOb osteogenic differentiation assay 47-48 
 1.7.  Statistical analysis 48 
   2.  Animal study 48-51 
 2.1.  Animals 48 
 2.2.  Preparation of the activated platelet concentrate 48 
 2.3.  Experimental design and surgical procedure 49-50 
 2.4.  Histological and histomorphometric evaluations 50-51 
 2.5.  Statistical analysis 51 
RESULTS 52-61 
   1.  In vitro study 52-59 
 1.1.  Platelet concentration in PC 52 
 1.2.  Cell proliferation 52-55 
 1.3.  Cell viability 55-56 
 1.4.  Inter-donor and cell population-origin variability 56-57 
 1.5.  hASC and hOb osteogenic differentiation 57-59 
   2.  Animal study 59-61 
 2.1.  Histological analysis 59-61 
 2.2.  Histomorphometric analysis 61 
DISCUSSION 62-69 
REFERENCES 70-91 
Abstract 
 
3 
 
Abstract 
 
During the last decades, the combination of cellular and molecular biology and 
mechanical engineering, has stimulated the development of new 
multidisciplinary fields in biomedical sciences, such as tissue engineering and 
regenerative medicine. The primary goal of these approaches is to provide an 
alternative to organ and tissue transplantation, by creating viable substitutes for 
damaged or diseased organs and tissues. 
Tissue healing is a complex process that involves a cascade of cellular and 
molecular events, that are mostly shared by the different tissues of the body. 
Interestingly, the tissue repair process initiates immediately after a traumatic 
injury and is mediated and controlled by a wide range of cytokines, proteins and 
growth factors released from platelets upon activation. Consequently, many 
growth factors have being considered as therapeutic molecules for the repair or 
regeneration of a wide range of tissues. Although their role has been only 
partially elucidated, the potential benefit of most growth factors has been 
demonstrated. In the last few years, the development of platelet-rich 
preparations has revolutionized the field of regenerative medicine, due to the 
repair capacities of the platelet-released growth factors, that stimulate and 
accelerate both soft and hard tissue healing and regeneration. Today, platelet 
concentrates are used in a wide range of disciplines such as dentistry, oral 
surgery, orthopedics, sport medicine, dermatology, and plastic and 
reconstructive surgery. Currently, different techniques to obtain these 
hemocomponents are available, each leading to preparations that may differ in 
platelet concentration, leukocyte and fibrin content. Among them, there is 
Plasma Rich in Growth Factors (PRGF), a preparation rich in platelets, easily 
obtained from a small volume of patient’s blood, which, being autologous, does 
not promote any immune reaction and infectious disease transmission. 
Additionally, leukocytes are excluded from PRGF, so as to avoid any pro-
inflammatory effects. Despite the growing craze for platelet concentrates 
technology, the scientific literature reported controversial results regarding the 
beneficial effect of these preparations on tissue healing, especially for bone 
regeneration. 
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Considering all this information, the aim of our research was to developed a 
study model in order to gain more information about the biological effect of a 
platelet concentrate on both soft and hard tissue regeneration. 
For this purpose, human adipose-derived stem cells (hASCs), human 
osteoblasts (hObs) and human dermal fibroblasts (hDFs) cultured in the 
presence of PRGF, were studied. Usually, cells used for human therapy are 
expanded in fetal bovine serum (FBS), but this way carries the risk of potential 
immunogenic residual bovine proteins exposure and possible contamination 
with infectious agents, likely generating immune responses in patients. 
Therefore, in this study, FBS was completely substituted by the platelet 
concentrate for the cells culture. Interestingly, PRGF never affected cell viability 
and, after a short adaptation period, both hASCs and hDFs grown in the 
presence of PRGF, increased their proliferation rate compared to standard 
culture condition, while hObs growth was evident only without any cell’s 
detachment. Furthermore, neither donor nor cell population effect on both cell 
viability and proliferation was observed. Regarding osteo-differentiation, alkaline 
phoshatase (ALP) activity was induced in both hASCs and hObs, with a peak at 
day 7 and 14, respectively. 
In parallel, in order to elucidate the clinical benefit of platelet concentrates in 
hard tissue repair, the combination of a bone graft substitute with PRGF in 
enhancing a bone defect regeneration performed in a preclinical animal model, 
was also investigated. In particular, bilateral circular critical lesions were created 
in the proximal tibia of six New Zealand rabbits, for a total of 12 defects, filled 
with the bone substitute alone or in association with PRGF. Untreated defects 
were also included as control. No side-effects have been observed during the 8 
weeks follow-up. Both histological and histomorphometric analysis showed a 
non-significant difference between treatment groups in terms of bone density, 
even if the addition of PRGF to the bone substitute seemed to induce a higher 
percentage of newly formed bone. 
In conclusion, this in vitro and in vivo study provided the evidence of the 
beneficial effect of platelet concentrates in both soft and hard tissue 
regeneration, thus supporting the application of this technology in clinical 
regenerative therapies. 
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Introduction 
 
1. Platelets 
Platelets, also called thrombocytes, form in the bone marrow and are 
cytoplasmic fragments of megakaryocytes with a discoid shape that range from 
1 to 3µm in diameter. These small cells lack a nucleus, but contain a highly 
organized cytoskeleton, an unique receptor and specialized secretory granules 
(α, β and γ) [1]. Approximately 140,000 to 400,000 platelets/mm3 circulate into 
the human bloodstream for 7-10 days before removal by macrophages of the 
reticuloendothelial system [2]. 
1.1. Megakaryocyte development 
Megakaryocytes (MKs) are platelet progenitor cells and the final stage of 
megakaryocyte development is the platelet production. Megakaryocytes are the 
largest (50-100µm) and one of the rarest myeloid cells (~0.01% of nucleated 
bone marrow cells) that reside primarily in the bone marrow, but are also found 
in the lung, the peripheral blood and during early mammalian development in 
the yolk sac, fetal liver and spleen [3]. They are highly specialized precursors 
cells that possess the role of producing and releasing platelets into the 
circulation and maintaining appropriate circulating platelets levels [4]. 
Megakaryocytes develop from pluripotent hematopoietic stem cells that give 
rise to two types of precursors: burst-forming cells (BFU-Meg) and colony-
forming cells (CFU-Meg), both of them expressing the CD34 antigen [5]. The 
promegakaryoblast is the first morphologically recognizable megakaryocyte 
precursor in bone marrow, while the megakaryoblast (or stage I megakaryocyte) 
is a more mature cell with a distinct morphology, 15 to 50µm in diameter, large 
kidney-shaped nucleus that has two sets of chromosomes (4N) and a basophilic 
cytoplasm lacking granules [4]. The promegakaryocyte (or stage II 
megakaryocyte) is 20 to 80µm in diameter and has a polychromatic cytoplasm 
less basophilic also containing developing granules. The development of cells 
culminates in the formation of megakaryocyte (Figure 1). The principal cytokine 
required for megakaryocyte maturation is the thrombopoietin (TPO), also known 
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as the primary regulator of thrombopoiesis [6], that acts in conjunction with 
Interleukins (IL-3, IL-6 and IL-11) and stem cell factor (SCF; kit ligand) [7]. 
 
Figure 1. Megakaryocyte maturation and development. Adapted from 
Platelet, Second Edition, Alan D. Michelson. 
 
Megakaryocytes undergo multiple DNA replications without cell division during 
endomitosis, a TPO-dependent process by which MKs become polyploidy [8]. 
An additional maturation event that occurs after the endomitosis completion is 
the cytoplasmic expansion phase, in which cytoplasm rapidly fills with platelet-
specific proteins and organelles, and an elaborated membranous network of 
cisternae and tubules, called the demarcation membrane system (DMS) in 
continuity with the plasma membrane, is formed [9]. The DMS is currently 
known to function as a membrane reservoir for proplatelets formation, the 
precursors of platelets [10, 11]. 
 
1.2. Platelet formation 
 
The final stage of megakaryocytopoiesis is the production of mature MKs able 
to release sufficient functional platelets to maintain hemostasis. Despite it has 
been well accepted the importance of platelets and that they derive from 
megakaryocytes, the mechanism by which platelets are assembled by their 
precursors is still controversial. To explain how platelets form and release from 
MKs, three models have been proposed. The first is cytoplasmic fragmentation 
via the DMS and predicts that DMS demarcates predetermined platelet-size 
fields within the megakaryocyte cytoplasm and that the fragmentation of 
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cytoplasm along these fracture lines releases platelets [12]. The second model 
is platelet budding from megakaryocytes surface in which platelets pinch off 
from blebs localized at periphery of the megakaryocyte cytoplasm [13]. The 
third is proplatelet formation and according to this model mature MKs extend 
long, branching processes called proplatelets into the sinusoidal blood vessels 
of the bone marrow [14]. Platelets assemble and package their organelles de 
novo within proplatelets and the intracellular components of platelets are sent 
from their synthesis sites in the MK cell body to the proplatelets. Individual 
platelets generate from massive fragmentation of the megakaryocyte cytoplasm 
along DMS fracture lines residing between these fields (Figure 2a). The 
extruded multi-lobed nucleus remains in the MK cell body, as the rest of the MK 
is transformed into proplatelets, and undergoes degradation by apoptosis 
(Figure 2b) [1]. 
 
 
Figure 2. (a) Mechanisms of platelet formation. (b) Cytoskeletal mechanics 
of platelet biogenesis detail in proplatelet model. Adapted from Platelet, 
Second Edition, Alan D. Michelson. 
 
1.3. Platelet structure 
 
The platelet plasma membrane has a fine, rugose appearance (Figure 3). 
These gyri and sulci may provide additional membrane needed when platelet 
spread on surfaces [15]. Small openings of the surface connected canalicular 
system (SCCS) are randomly dispersed on the platelet exterior surface 
connecting the channels and the surface membrane. 
a b 
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Figure 3. Discoid platelet (magnification x30.000). Adapted from Platelet, 
Second Edition, Alan D. Michelson. 
The platelet plasma membrane has a thicker exterior coat, called glycocalyx, 
covered with major and minor glycoprotein receptors necessary to facilitate the 
first contact during the platelet hemostatic response at sites of vessel injury [16-
19]. The lipid bilayer of the peripheral zone on which the glycocalyx rests is 
incompressible and cannot stretch [20]. The submembrane area contains a 
relatively regular system of thin filaments similar to actin ones that play an 
important role in the shape change and receptor and particles translocation over 
the exterior cell surface [21]. In the platelet cytoplasm can be identified small 
numbers of relatively simple mitochondria that are essential in energy 
metabolism. 
Platelets contain three major types of secretory organelles - α granules, dense 
bodies (δ granules) and lysosomes - and occasionally multivescicolar bodies 
that serve as sorting stations in the development of such granules [22]. These 
granules types contain a number of proteins with autocrine and paracrine 
functions, including adhesive proteins, coagulation factors, chemokines, 
cytokines, growth factors, proteoglycans, immunoglobulins, proteases and 
protease inhibitors [23]. 
• α Granules are the most abundant platelet organelles and their number 
depends on the platelet size and the presence of other structure that occupy the 
space. There are approximately 40 to 80 α granules per platelet, but larger and 
giant cells may contain over 100, ranging from 200 to 500nm in diameter and 
round to oval shape [24]. α Granules interior structure is divided into zones. 
They include: the peripheral membrane of the granule, the electron dense 
nucleoid containing chemokines and proteoglycan, a less electron dense area 
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near the nucleoid with fibrinogen, and a peripheral electronluscent zone that 
contains von Willebrand factor [25]. Their function derives from their content 
that includes both membrane bound proteins then expressed on the platelet 
surface and soluble proteins released into the extracellular space (Table 1) [26]. 
• Dense bodies are smaller than α granules, fewer in number (about 1 to 1.4 
dense body per platelet) and with a high morphological variability [26]. Some of 
them have an irregular form, filaments that extend from the dense inner core to 
the enclosing membrane and contain a granule-like substance that fill the empty 
space otherwise unfilled (Table 2). 
Table 1. α Granules content. Adapted from Platelet, Second Edition, Alan D. 
Michelson. 
Adhesion molecules 
P-Selectin, von Willebrand factor, thrombospondin, 
fibrinogen, integrin αIIbβ3, integrin αvβ3, fibronectin 
Chemokines 
Platelet basic protein [platelet factor 4 and its variant 
(CXCL4) and β-thromboglobulin], CCL3 (MIP-1α), 
CCL5 (RANTES), CCL7 (MCP-3), CCL17, CXCL1 
(growth-regulated oncogene-α), CXCL5 (ENA-78), 
CXCL8 (IL-8) 
Coagulation pathways Factor V, multimerin, factor VIII 
Fibrinolytic pathway 
α2-Macroglobulin, plasminogen, plasminogen activator 
inhibitor 1 
Growth and 
angiogenesis 
Basic fibroblast growth factor, epidermal growth factor, 
hepatocyte growth factor, insulin-like growth factor 1, 
transforming growth factor β, vascular endothelial 
growth factor-A, vascular endothelial growth factor- C, 
platelet-derived growth factor 
Immunologic 
molecules 
β1H Globulin, factor D, c1 inhibitor, IgG 
Other proteins 
Albumin, α1-antitrypsin, Gas6, histidine-rich 
glycoprotein, high molecular weight kininogen, 
osteonectina protease nexin-II (amyloid beta-protein 
precursor) 
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Table 2. Dense granules content. Adapted from Platelet, Second Edition, Alan 
D. Michelson. 
• Lysosomes are fewer in number, in fact there are no more than three and 
usually zero to one lysosome per platelet. They are spherical in form, slightly 
smaller than α granules and contain at least 13 acid hydrolases, cathepsin D 
and E, the lysosomal membrane proteins LAMP-2 and CD63 [27-29]. The 
lysosomes appear to have no significant role in platelet function, but just to be 
vestigial remnants. 
Recent proteomic studies suggested that platelets possess an extensive 
transcriptome and proteome in addition to prestored mediators, and although 
they lack a nucleus and hence genomic DNA, platelets contain messenger RNA 
(mRNA) and the translational machinery required for protein synthesis [30, 31]. 
1.4. Platelet functional role in hemostasis 
The major physiological function of circulating platelets is to detect damage to 
the walls of blood vessels. When damage is detected they respond rapidly, 
hence platelets provide the first line of defense in stopping the loss of blood 
following vascular injury by adhering to the site of wound. In an intact system 
platelets circulate in a quiescent state, near the endothelial cells lining of blood 
vessels without forming stable adhesions, but after disruption of the integrity of 
the vascular tissue, platelets are exposed to damaged blood vessels and 
become in direct contact with subendothelial matrix proteins including von 
Willebrand factor (VWF), collagen, fibrinogen and fibronectin, normally covered 
by endothelial cells [32-35]. This interaction lead to platelets aggregation, to the 
change from a rounded shape to one that includes large, sticky protuberances, 
or pseudopodia (Figure 4) [36], and to the formation of a platelet plug that 
reduces or temporarily stops the loss of blood. This process is called platelet 
activation and represents an essential step in hemostasis. 
Ions Ca, Mg, P, pyrophosphate 
Nucleotides ATP, GTP, ADP, GDP 
Membrane proteins CD63 (granulophysin), LAMP 2 
Transmitters Serotonin 
Introduction 
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Figure 4. Platelet shape change and aggregation. Resting (left), partially 
activated (middle) and fully activated (right) platelets. Adapted from Platelet, 
Second Edition, Alan D. Michelson. 
During activation, the α granules fuse with the platelet plasma membrane and 
release to the surrounding their protein and small molecules content that 
accelerate and increase platelet plug formation and initiate the tissue repair 
process [37]. Adenosine diphosphate (released by activated platelets), thrombin 
and adrenaline are other factors that mediate platelet activation [35]. In case of 
small vascular damage, this platelet plug may be able to stop blood loss, but if 
the defect is large, the generation of a blood clot may be necessary. The 
coagulation cascade is initiated by one of two pathways, called the extrinsic and 
intrinsic pathways [35]. 
 
Introduction 
 
12 
 
 
Figure 5. Coagulation cascade. The intrinsic and extrinsic pathways converge 
at the factor IX activation level. 
The extrinsic pathway begins after the contact between a tissue factor located 
in the tissue adventitia and the blood after vascular injury, whereas the intrinsic 
pathway is initiated by damage or alteration of the blood. Despite the two 
pathways begin differently, they converge and share many of the latter steps in 
the cascade reaction (Figure 5). Both pathways involve a cascade of events by 
which inactive factors become active that in turn catalyze the formation of other 
products from precursors, leading to the final formation of a fibrin clot. Calcium 
ion is required for the completion of the reaction, while platelets participate at 
multiple levels in the fibrin threads generation and are part of the final clot which 
is formed by a fibrin mesh, the activated platelet aggregate, and red and white 
blood cells within them. To further close the blood vessel, the clot retracts by 
means of the platelet actin-myosin fibers contraction by 20 minutes to 1 hour 
after clot formation [38]. Hemostasis is also facilitated by local vasoconstriction 
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in response to thromboxane and serotonin release from the platelet aggregate 
[39]. 
1.5. Platelet functional role in wound healing 
The repair process starts immediately after tissue damage and hemostasis can 
be considered to be the first stage of wound healing [40]. Traumatic injury to the 
skin initiates a cascade of events characterized by three overlapping stages 
known as inflammation, new tissue formation and tissue remodeling, that, as 
result, lead to at least partial reconstruction of the damaged area (Figure 6) [41]. 
Inflammation is the initial response to tissue injury and aims to provide a rapid 
hemostasis and the formation of the blood clot, as previously described. The 
clot has two functions: it represents a barrier that temporarily protects the 
denude tissue against invading microorganisms, and it works as a provisional 
matrix to maintain the regenerative space and provide a scaffold for cell 
migration and proliferation [41, 42]. Within a few hours after injury, inflammatory 
cells invade the clot (early stage of inflammation). 
 
 
Figure 6. (a) Schematic representation of different stages of wound 
healing. (b) Phases of wound repair. Adapted from Polimeni et al., 
Periodontol 2000 2006;41:30-47. 
Neutrophils arrive first within a few minutes followed by monocytes and T 
lymphocytes, and clean the wound of bacteria and tissue debris through 
phagocytosis and the release of enzymes and reactive oxygen products. Next, 
a b 
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monocytes differentiate to macrophages and become the predominant cell type. 
Within 3 days, the inflammatory reaction moves into the late phase where 
macrophages migrate into the wound area, assist neutrophils in their function 
and secrete polypeptide mediators targeting cells involved in the wound healing 
process [41, 42]. Macrophages secrete also growth factors and cytokines that 
initiate the proliferative stage of wound repair. The latter begins with the 
migration and proliferation of keratinocytes and dermal fibroblasts into the 
wound area, where they deposit large amounts of extracellular matrix. Blood 
vessel endothelial cells also proliferate and form new capillaries that extend into 
the injured site, beginning a massive angiogenesis process [43]. The resulting 
connective tissue, called granulation tissue for the pink, soft, granular 
appearance, undergoes maturation and remodeling. During this third and final 
phase of wound healing, the newly generated tissue reshapes and reorganizes 
in order to repair (scar formation) or regenerate the injured tissue closely 
resembling the original one. Fibroblasts produce a new collagen-rich matrix and 
approximately 1 week after injury, some of them transform into myofibroblasts 
and express α-smooth muscle actin responsible for contraction [44, 45]. This 
final stage of healing can require years for completion[43]. Soft tissue heals by 
scar tissue formation that differs from normal one as it consists primarily of 
fibroblasts and matrix, and may restore integrity but not form and function. On 
the other hand, bone typically heals without scar, in fact, the new formed tissue 
cannot be distinguished from the existing bone [43]. 
 
2. Platelet growth factors 
Wound healing and tissue repair require a sequence of events, including 
undifferentiated cells recruitment, cell division and differentiation, modulated by 
a wide variety of different growth factors (GFs) and cytokines, primarily stored in 
the α granules of platelets and released upon activation [46]. Growth factors are 
polypeptides that transmit signals to modulate cellular activities. In fact, they 
have the potential to stimulate, support, enhance or inhibit growth, 
differentiation, migration, adhesion and gene expression of various cell types 
towards specific phenotypes, which leads to accelerated tissue regeneration 
[47]. Many cell types can produce the same growth factor and the same growth 
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factor can act on many cell types (pleitropism) with the same or different effects. 
In addition, different GFs can share the same biological effect (redundancy) and 
can influence the secretion and action of other growth factors (antagonize or 
enhance). Platelet growth factors act binding to the extracellular domain of a 
specific GF-receptor on the surface of target cells. Depending on the proximity 
of their synthesis site to the action ones, growth factors binding through 
autocrine (target cell is the same that secreted the growth factor), paracrine 
(target cell is nearby), endocrine (target cell is distant), juxtacrine (target cell is 
apposed to the growth factor/receptor complex), and/or intracrine (growth 
factor/receptor complex is internalized) mechanisms, which, in turn, activate the 
intracellular signal-transduction pathways: a second messenger transmits the 
signal into the cell, eliciting a physiological response (Figure 7) [48]. Growth 
factors usually exist as inactive or partially active precursors that require 
proteolytic activation, and may need to bind to matrix molecules for activity or 
stabilization [49]. Hundreds of growth factors have been identified, 
characterized and, based on structural homologies, grouped into several 
families and super-families [50]. Among them there are: platelet-derived growth 
factor (PDGF), fibroblast growth factor (FGF), transforming growth factor-β 
(TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor 
(IGF) and epidermal growth factor (EGF). Furthermore, growth factors possess 
a short biological half-lives [51]. Although several studies have demonstrated a 
beneficial effect of many of these growth factors on the healing process both in 
animal models and also in patients [52, 53], the suggested function of these 
endogenous molecules have been only partially elucidated, and in most cases it 
is based on descriptive expression studies and/or functional cell culture data. 
Therefore, the in vivo roles of many growth factors remain largely unconfirmed 
[46]. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Growth factors’ signaling pathway.
signaling pathways that drive pleiotropic cellular responses. 
Sebolt-Leopold et al., 
signals the cell cycle control system. Copyright © 2003 Pearson Education, Inc., 
publishing as Benjamin Cummings.
 
2.1. α Granules growth factors
The principle growth fact
a. Platelet-derived growth factor (PDGF)
PDGFs comprise a family of homo
PDGF-AA, PDGF-AB, PDGF
function by binding to three different transmembrane tyrosine kinase recepto
which are homo- or heterodimers of an 
growth factor shown to be chemotactic for cells migrating into the healing skin 
wound, such as neutrophils, monocytes, and fibroblasts. In addition, it enhances 
proliferation of fibroblasts and the production of extracellular matrix by 
cells, it stimulates fibroblasts to contract collagen matrices and it induces the 
myofibroblast phenotype in these cells 
be a major player in wound healing. Furthermore, PDGF was the first growth 
factor to be approved for the treatment of human ulcers 
PDGF was considered to play an important role in the repair process, since 
a 
 (a) Central growth factor 
Nature 2006;441:457-462. (b) How a growth factor 
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-BB, PDGF-CC, and PDGF-DD, that exert their 
α- and a β-chain [54]. PDGF is the first 
[55]. Thus it has long been suggested to 
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early after injury it is released in large amounts from degranulating platelets 
[57], and it is present in wound fluid [58]. On the other hand, augmented PDGF 
production might be involved in the pathogenesis of hypertrophic scars and 
keloids as suggested by the potent effect of PDGF on fibroblast proliferation 
and extracellular matrix production by these cells, the presence of enhanced 
levels of this growth factor in hypertrophic scar tissue [59], and the increased 
responsiveness of keloid fibroblasts to PDGF [60]. 
b. Fibroblast growth factor (FGF) 
FGFs comprise a growing family of structurally related polypeptide growth 
factors, currently consisting of 22 members [61] that transduce their signals 
through four high-affinity transmembrane protein tyrosine kinases, FGF 
receptors 1-4 (FGFR1-4) [62], which bind the different FGFs with different 
affinities. Most FGFs bind to a specific subset of FGF receptors, FGF1, binds to 
all known receptors, while FGF7 specifically interacts with a splice variant of 
FGFR2, designated FGFR2IIIb [63]. One characteristic feature of FGFs is their 
interaction with heparin or heparan sulfate proteoglycans that is essential for the 
activation of the signaling receptors [64] and that stabilized FGFs to thermal 
denaturation and proteolysis, strongly limiting their diffusibility. Most members of 
the FGF family stimulate the proliferation of a broad variety of mesodermal, 
ectodermal, and also endodermal origin cells, with the only exception of FGF7 
(keratinocyte growth factor, KGF), which seems to be specific for epithelial cells, 
at least in the adult organism [65]. In particular, FGFs are mitogenic for several 
cell types present at the wound site, including fibroblasts and keratinocytes [66]. 
In addition to their mitogenic effects, FGFs also regulate the migration and 
differentiation of their target cells, and some of them have been shown to be 
cytoprotective and to support cell survival under stress conditions [65]. 
Furthermore, FGF1 and FGF2 were shown to stimulate angiogenesis in various 
assay systems [67]. FGFs are therefore candidates for contributing to the 
wound healing repair. 
c. Epidermal growth factor (EGF) 
The epidermal growth factor (EGF) family comprises several members, 
including EGF, transforming growth factor-α (TGF-α), heparin-binding EGF (HB-
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EGF), amphiregulin, epiregulin, betacellulin, neuregulins, the recently 
discovered epigen, as well as proteins encoded by Vaccinia virus and other 
poxviruses [68, 69]. In addition, more distantly related proteins known as 
neuregulins (heregulins, neu differentiation factors, NDF 1-4) can also bind to 
some EGF receptor family members [70]. All these growth factors exert their 
functions by binding to four different high-affinity receptors, EGFR/ErbB1, 
HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. Overexpression of these 
receptors, in particular of HER2, is often found in human cancers and is likely to 
have a causative role in tumorigenesis. In addition, EGF, TGF-α and HB-EGF 
have demonstrated a positive effect on wound repair in a series of experimental 
and clinical studies, suggesting that these endogenous growth factors are also 
involved in the healing process [71]. 
d. Vascular endothelial growth factor (VEGF) 
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and 
placenta growth factor (PLGF) that exert their biological functions by binding to 
three different transmembrane tyrosine kinase receptors, known as VEGFR-1, 
VEGFR-2, and VEGFR-3. The biological functions of VEGF-A and its receptors 
VEGFR-1 and VEGFR-2 have been characterized in most detail and it has been 
identified as the major regulator of vasculogenesis and angiogenesis during 
development, indicating that VEGF might also be involved in the regulation of 
angiogenesis during wound healing [72]. 
e. Insulin-like growth factor (IGF) 
IGF-I and IGF-II stimulate mitogenesis and survival of many different cells 
types, through the type I IGF receptor, a tyrosine kinase that resembles the 
insulin receptor. IGF-II also binds to the IGF type II/mannose-6-phosphate 
receptor, resulting in the internalization and degradation of IGF-II [73]. The 
availability of free IGF for interaction with the IGF-I receptor is modulated by six 
IGF-binding proteins (IGFBPs) that have also been shown to have IGF 
independent effects on cell growth [74]. IGFs exert their functions in an 
autocrine, paracrine, or endocrine manner. In addition, several studies have 
revealed a beneficial effect of exogenous IGF-I on wound healing, in particular 
in combination with other growth factors [75]. 
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f. Nerve growth factor (NGF) 
Nerve growth factor (NGF) is the prototype for the neurotrophin family of 
polypeptides, which are essential for the development and survival of certain 
sympathetic and sensory neurons in both the central and peripheral nervous 
systems [76]. It plays a key role in the initiation and maintenance of 
inflammation in various organs, therefore NGF has been suggested to be also 
involved in cutaneous wound repair, since exogenous NGF was shown to 
accelerate wound healing in normal and healing-impaired diabetic mice [77, 78], 
and to promote the healing of pressure ulcers in humans [79]. 
g. Transforming growth factor-β (TGF-β) 
The TGF-β superfamily comprises a wide range of proteins, many of which play 
important roles during development, homeostasis, disease, and repair. The 
structurally related but functionally distinct mammalian members include TGF-
β1, -β2, and -β3, bone morphogenetic proteins (BMPs), Mullerian inhibiting 
substance, nodals, inhibins, and activins [80]. Their biological effects are 
mediated by heteromeric receptor complexes, which activate intracellular 
signaling cascades [81]. The three mammalian TGF-β isoforms are synthesized 
as latent precursors, usually secreted as a complex with latent TGF-β-binding 
protein, then extracellularly removed via proteolytic cleavage. Active TGF-βs 
exert their biological functions via binding to a heteromeric receptor complex, 
consisting of one type I and one type II receptor, both of which are serine-
threonine kinases. In addition, they bind with high affinity to a nonsignaling type 
III receptor, which functions mainly to present TGF-β to the type II receptor [82]. 
In vitro, the three TGF-β isoforms have been shown to be mitogenic for 
fibroblasts, but they inhibit proliferation of most other cells, including 
keratinocytes. Furthermore, they are very potent stimulators of the extracellular 
matrix proteins and integrins expression [83]. Thus, they are among the most 
studied molecules in the wound healing scenario. 
A multitude of cytokines and chemokines are also stored and released by 
platelet α granules [46, 84]. 
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2.2. Growth factors biologic effects 
Tissue regeneration is a complex biological process that involves a vast number 
of molecules and a broad cascade of events [46, 85], including cell proliferation 
and differentiation, modulated by a number of cytokines and growth factors that 
provide local signals at sites of injury [86]. Determining the roles that growth 
factors play in tissue repair and regeneration is important in order to design, 
develop and apply suitable formulations that release them with a spatiotemporal 
control for the functional and accelerated repair of the tissue [87]. 
a. Hard tissue regeneration 
Bone tissue, which consists of mineralized matrix and cells, [88] originates from 
mesenchymal stem cells, and its growth and remodeling are regulated by 
cytokines, growth factors and hormones [88-90]. In bone healing humoral and 
cellular events cooperate in order to re-establish revascularization, matrix 
synthesis and mineralization, and hematopoiesis restoration [91]. Fracture 
repair is a complex process with initial stages similar to those observed in 
healing after soft tissue injured, but although both healing responses involve 
new tissue formation at the injured site, soft tissues heal by replacing the injured 
tissue with a fibrous scar, whereas bone heals by regeneration of the normal 
osseous anatomy. Fractured bones heal by a cascade of cellular events in 
which mesenchymal cells respond to unknown regulators by proliferating, 
differentiating, and synthesizing extracellular matrix, and different steps in this 
cascade may be regulated by growth factors [92]. Bone healing begins 
immediately after injury, when growth factors are released into the fracture 
hematoma by platelets and inflammatory cells. At later times, growth factors in 
the callus, presumably regulate additional steps in the fractured bone repair, 
suggesting that these molecules are central regulators of cellular proliferation, 
differentiation, and extracellular matrix synthesis during fracture repair. 
Furthermore, abnormal growth factor expression has been implicated as 
causing impaired or abnormal healing in other tissues, suggesting that altered 
growth factor expression may also be responsible for abnormal or delayed 
fracture repair [93]. 
However, there is a significant lack of consensus regarding the biological effect 
of GFs on primary human osteoblasts, as several studies reported success in 
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promoting bone regeneration [94-96], while others referred negative findings 
[97, 98]. Furthermore, in literature the investigation of GFs is described mainly 
in humans or animals [97, 99], while the amount of in vitro studies for basic 
research is limited [100]. 
b. Soft tissue regeneration 
Angiogenic growth factors have been demonstrated to enhance soft tissue 
healing accelerating epidermal regeneration in cutaneous wound. There are 
four major families of angiogenic growth factors: fibroblast growth factor (FGF), 
transforming growth factor β (TGF-β), platelet-derived growth factor (PDGF), 
and epidermal growth factor (EGF), and each of them has the ability to induce 
soft tissue vascular proliferation in microgram quantities, offering a promising 
potential in soft tissue wound healing [101]. Compared with any other soft tissue 
sites, growth factors have been studied most extensively in skin, since its poor 
wound healing is a common clinical problem derived from many reasons, 
including irradiation, chronic venous stasis, diabetes, burns, and pressure 
necrosis. Furthermore, skin wounds are much more accessible for growth 
factors applications observation and for wound-healing measurements. For a 
normal healing, skin injure requires adequate collagen/matrix turnover, 
angiogenesis and epithelialization, but if one component is delayed, normal 
healing is significantly hindered, leading to patient morbidity and mortality. 
Several clinical trials studying the effects of growth factors on chronic skin 
wounds, from diabetes to venous stasis ulcers have been performed over the 
last 10 years. Some of these preclinical and clinical studies have shown 
promising results [102-105], whereas others [106, 107] did not find positive 
effects. What primarily emerged from these investigations is that the state of a 
healing wound not only depends on its growth factor milieu, but also on other 
variables such as wound care, tissue oxygen level, bacterial count, and 
nutritional status of the patient [108]. Most clinical trials have been conducted by 
topical growth factors application to the wound and by testing the effect of a 
single growth factor on dermal injures. Some researchers believe that the 
administration of growth factors in combination could be more effective to 
improve wound healing, than the use of a single agent alone. This was 
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suggested by the demonstration that many growth factors can synergistically 
interact with each other [109]. 
 
3. Platelet concentrates 
Platelets represent a potential source of multiple autologous growth factors and 
proteins involved in tissue regeneration. In order to improve healing on a 
surgical site, many biological products trying to mimic the natural wound healing 
process, have been developed. This effort dates back many years ago with 
fibrin glue, and recently turned into platelet concentrates technology [110]. 
Platelet concentrate (PC) is a blood-derived product with a platelet 
concentration above baseline, produced by a centrifugation procedure in order 
to concentrate and collect most platelets from the harvested blood, and 
designed for the local release of platelet growth factors essential to enhance 
healing [111]. The initial rationale of platelet-rich products was the replacement 
of blood clot with a preparation enriched in platelets that once activated, could 
secrete a large pool of proteins and factors driving the tissue regeneration 
mechanism. Eliminating erythrocytes and, in some cases, leukocytes, the 
preparation would take full advantage of the concentrated platelets and the 
stored growth factors, enabling an accelerated wound healing and tissue 
regeneration [112]. 
3.1. History of the medical use of platelet concentrates 
The development of devices that may decrease bleeding, reduce operative time 
and improve the quality of surgical tissue management is a rapidly expanding 
area of research and clinical use. Thus, topical hemostats, sealants and 
adhesives are important elements for surgical practice [113]. 
a. Fibrin glue 
Fibrin glue is the first product introduced for medical purpose and the only one 
approved by the Food and Drugs Administration (FDA) for indications in all 
three of these categories. Its use was first described by Bergel in 1909 [114] 
and Grey in 1915 [115] as a hemostatic agent, while during World War I, fibrin 
patches were used to stop bleeding from parenchymatous organs. In 1940 
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Young and Medawar [116] applied fibrinogen as an adhesive for peripheral 
nerves. The combination of fibrinogen and bovine thrombin was employed in 
1944 by Tidrick and Warner [117] in the attempt to accelerate the fibrin clot 
formation and to improve skin grafts. In the 1970’s Matras and colleagues [118] 
introduced a concentrated form of fibrinogen and the first commercial, 
multidonor fibrin sealant product became available in Europe. Dresdale and 
coworkers [119] first described the combination of autologous cryoprecipitates 
and bovine thrombin to create fibrin glue in 1985. Fibrin sealant is now 
approved in a broad variety of surgical and especially cardiovascular 
procedures, including neurosurgery, plastic, thoracic and oral surgery, 
gynecologic procedures and a large number of additional clinical applications 
[120, 121]. Fibrin glue is a mixture of components involved in blood clotting that 
mimics the last phase of the physiological coagulation cascade, through the 
conversion of fibrinogen to fibrin by thrombin, leading to the formation of a fibrin 
clot. Fibrin glue consists of two components usually contained in separate 
syringes, a fibrinogen with factor XIII solution and a calcium ions-rich-thrombin 
solution. The mixing of the two components leads the thrombin to the cleave of 
the fibrinogen into fibrin and, in the presence of ionized calcium, to the 
simultaneous activation of factor XIII, which then cross-links fibrin to form an 
organized clot [122]. Fibrinogen could be isolated from either pooled blood 
(blood from several donors) or single donor blood (autogenous or allogenic) 
using centrifugation in combination with either cryoprecipitation or precipitation 
using different agents (ethanol, ammonium sulphate or polyethylene glycol) 
[123]. Before solubilization for reconstitution the precipitate undergoes viral 
inactivation using solvent/detergent or dry heat, sterilization and freeze-drying 
[124]. Fibrin glue is formulated for topical use only and not for systemic 
administration, and is probably one of the most complex human plasma 
derivatives both in terms of composition and clinical uses that, the latter, 
depends on the mode of application and the physical properties of the resulting 
clot. This biologic product can be applied in different ways depending on the 
specific indication and the surface area being treated. For small localized areas 
sequential application (fibrinogen followed by thrombin solution) or 
simultaneous application of the 2 solutions to the repair site by a dual-syringe 
delivery device is possible (Figure 8). In this system, separate syringes 
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containing the two components enable a single plunger to dispense equal 
volumes of the fibrinogen and the thrombin concentrates passively mixed at the 
end of the delivery needle. For covering larger body surfaces sequential spray 
application (thrombin solution is sprayed on a surface previously sprayed with 
fibrinogen ones) may be used. A double syringe system made of multi-channel 
catheter connected to a pressurized gas source is also available: the two 
components are injected simultaneously into the channels and are dispersed by 
the continuous gas jet producing a thin fibrin film, thus ensuring homogeneous 
glue application on the wound surface. Fibrin glue can also be applied by 
collagen fleece, sponge, absorbable or nonabsorbable mesh and with or without 
the help of an endoscopic delivery device [125, 126]. 
 
Figure 8. Dual-syringe system for fibrin glue application. Adapted from 
Brennan M., Blood Rev 1991;5:2040-244. 
To avoid patient’s allergic reactions and the hypothetical risks of infectious 
agents transmission, today are available commercial fibrin glues with human 
and recombinant thrombin in place of bovine origin. 
Wound repair involves a complex interaction between biochemical amplification 
cascades, circulating platelets and monocytes, locally acting growth factors, and 
skin and connective tissue cells, therefore fibrin glue imitating the last steps of 
the coagulation cascade is only a part of the wound healing process [127]. To 
avoid the risk of infectious disease transmission from commercially available 
fibrin glue systems, the development of different autologous techniques has 
been proposed, but the request of patient interaction with the blood bank few 
days before the surgery, clerical error by blood bank and the failure to meet the 
blood bank’s criteria, disqualify autologous fibrin glues usage [128]. 
Furthermore, these autologous preparations were only used as fibrin tissue 
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sealants rather than healing stimulators. In fact, platelets were only supposed to 
support the fibrin polymerization and growth factors and healing properties were 
not considered. Also, due to the limited tensile strength and the lack of growth 
factors, fibrin glue has been recognized as not being ideal for wound and tissue 
healing [129], therefore, the use of the circulating platelet as a source of 
autologous locally acting growth factors has been introduced. These platelet-
rich products were named platelet gels and were considered an autologous 
modification of fibrin glue [130]. Platelet gel is prepared by mixing platelet-rich 
plasma derived from an empirical 2-steps gradient density centrifugation of 
autologous whole blood (collected immediately preoperatively), with thrombin 
and calcium chloride. The first clinical application was described by Knighton et 
al. in 1986 [109] for the treatment of chronic non-healing cutaneous ulcers, and 
a few years later by Whitman et al. [128] for oral and maxillofacial surgery. 
b. Platelet-rich plasma (PRP) 
Platelet concentrates technologies were originally introduced for the treatment 
and prevention of hemorrhage due to severe thrombopenia. The standard 
platelet concentrate for transfusion has been named “platelet-rich plasma” 
(PRP) and although the term PRP was first used in 1954 by Kingsley [131] 
during blood coagulation experiments, its use truly started with Marx et al. [132] 
in a study about bone graft reconstruction in maxillofacial surgery. PRP is a 
concentration of platelets in a small volume of plasma and differs from both 
fibrin glue and platelet gel [133]. The growing popularity of this product led to 
the development of a wide range of preparation protocols, kits and centrifuges, 
but all these commercial PRP techniques have some points in common. Blood 
is collected with anticoagulant just before or during surgery and is immediately 
processed by two-steps centrifugation: the first centrifugation (also called soft 
spin) separates the blood into three layers, red blood cells at the bottom, a buffy 
coat layer rich in leukocytes and platelets in the middle, and acellular plasma 
(platelet-poor plasma, PPP) at the top. PPP, PRP and few red blood cells are 
transferred to another tube without anticoagulant and centrifuged again. The 
second step (hard spin) differs between the numerous protocols, but it aims to 
separate the platelets from the PPP, including or not white blood cells (Figure 
9). The resulting platelet concentrate is then applied to the surgical site together 
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with thrombin and/or calcium chloride (or similar factors) in order to activate 
platelets and trigger fibrin polymerization [134]. 
 
 
Figure 9. PRP preparation using a two-steps centrifugation procedure. 
Adapted from Dohan Ehrenfest et al., Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 2006;101:e37-e44. 
c. Plasma Rich in Growth Factors (PRGF) 
In 1999, Anitua [135] described a manual version of the original PRP 
technology, using a one-step centrifugation process to obtain the three typical 
blood layers (red blood cells, buffy coat and acellular plasma) and several 
pipetting steps to entirely collect the final product named PRGF (Plasma or 
Preparation Reach in Growth Factors) (Figure 10). This platelet concentrate 
contains no leukocyte and lower platelet and growth factor concentrations than 
other products [136] and could be activated with 10% calcium chloride to induce 
fibrin polymerization and PRGF gel formation. 
Introduction 
 
27 
 
 
Figure 10. PRGF preparation using one-step centrifugation procedure. 
Adapted from Anitua et al., J Biomed Mater Res A. 2015;103:1011-1020. 
d. Platelet-rich Fibrin (PRF) 
The latest development of these protocols was introduced by Choukroun et al. 
in 2001 [137]. The PRF (Platelet-Rich Fibrin) technique was considered a 
second-generation platelet concentrate technology that differed from the other 
products for several characteristics: blood is collected without anticoagulant and 
immediately centrifuged. In the absence of anticoagulants and activators (i.e. 
thrombin or calcium chloride), platelet activation and fibrin polymerization are 
triggered immediately, leading to the natural formation of a strong PRF clot in 
the middle of the tube, red blood cells (RBC) in a base layer and an acellular 
plasma at the top (Figure 11) [110]. The PRF clot is a strong fibrin matrix in 
which most of the platelets and leukocytes are concentrated [138, 139] and that 
does not dissolve quickly after application, but is slowly remodeled similarly to a 
natural clot. 
 
Figure 11. PRF preparation. Adapted from Dohan Ehrenfest et al., Trends 
Biotechnol 2009;27:158-167. 
Sedimented  
red cells 
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3.2. Classification 
To date, several techniques for platelet concentrate preparation are available 
and, although each method leads to a different product in term of biological 
properties, most of these products were initially called PRP. This term was the 
same as the original transfusion platelet concentrates, but it does not permit to 
make a distinction between the numerous commercial systems and protocols 
necessary to make more informed decisions regarding platelet concentrate 
application in the clinical setting. In order to clarify between the extreme variety 
of biological preparations, together with a deriving plethora of terms, often very 
similar to each other, a full classification system for all platelet concentrates has 
been proposed in two main publications [134, 140]. 
According to Dohan Ehrenfest et al. [134] three main sets of parameters are 
necessary for the clear classification of platelet concentrates. The first set 
regards preparation kits, centrifugation parameters (number, speed and time of 
centrifugations), system type (automatized or manual), and costs; the second 
one relates to the content of the concentrate (platelet and leukocytes collection 
efficiency), and the third set concerns the fibrin network (fibrinogen 
concentration and fibrin density, and fibrin polymerization process). These 
parameters enable to classify all the available methods into four main 
categories on the basis of their leukocyte content and fibrin architecture: 
leukocyte-poor or pure platelet-rich plasma (P-PRP) without leukocytes, 
leukocyte- and platelet-rich plasma (L-PRP) with leukocytes, leukocytes-poor or 
pure platelet-rich fibrin (P-PRF) without leukocytes and leukocyte- and platelet-
rich fibrin (L-PRF) with leukocytes [134]. 
DeLong et al. [140] defined the “PAW classification system” an acronym that 
stands for Platelet, Activation, and White cells, to identify the PRP preparations 
based on three components: the absolute number of platelets (P), the manner 
in which activation occurs (A), and the presence or absence of white blood cells 
(W). 
The Dohan Ehrenfest’s classification is probably the easier and more accurate, 
even if few clarifications are still necessary in order to find a consensus 
terminology on platelet concentrate technologies, as in literature the lack of 
standardization and consistency makes it difficult for investigators to compare 
results between articles or to replicate published data. 
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3.3. Clinical and therapeutic applications 
The ability to prepare autologous platelet concentrates enjoyed a great increase 
in popularity, therefore the use of this technology spread in many different 
medical fields including dentistry, oral implantology, orthopedics, ulcer treatment 
and ophthalmology among others. 
Despite the great interest regarding the properties of platelet concentrates, 
reflected also in the large amount of published articles in this regard, the 
indications that their usefulness is fully demonstrated are few. Such conflicting 
data in literature could not be necessarily due to the absence of positive 
evidence, but frequently because of the particular animal model used (a higher 
concentration of platelets may aid in human wound healing, whereas other 
animal species may heal extremely well even without additional platelets, 
making it more difficult to show a benefit of platelet concentrate in these 
models), the different techniques, preparation protocols, kits and centrifuges 
used to concentrate platelets and prepare the PC (some isolation techniques 
may contribute to early and premature platelet degranulation), the post-
operative follow-up period (long-term data are preferred as PC exerts a direct 
influence upon only the initial phase of osseous healing, but physiological 
mechanisms still continue to promote osseous repair throughout the entire 
period of osseous maturation), the specific regenerative material combined with 
the platelet concentrate, and the clinical design employed (when platelet 
concentrates are used in combination with other components, their effect is 
masked). All these reasons may influence the clinical success of platelet 
concentrate. 
a. Oral and maxillofacial surgery and oral implantology 
In the dentistry and oral and maxillofacial surgery area, platelet concentrates 
have been used for the treatment of many clinical conditions (i.e. periodontal 
defects and post-extraction socket treatment, oral implant osseointegration, 
maxillary sinus augmentation and maxillofacial skeletal reconstruction). In 1994 
Tayapongsak et al. [141] introduced the novel idea of adding autologous fibrin 
adhesive to cancellous bone during mandibular continuity reconstruction, 
whereas the application of PRP to oral surgery was first described by Whitman 
et al. [128] and Marx et al. [132]. Whitman and coworkers in their 1997 article 
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suggested that platelet’s activation within the gel could enhance wound healing, 
while in 1998 Marx et al.’s study showed that the combination of PRP with 
autogenous bone for the treatment of mandibular continuity defects, resulted in 
a faster maturation and a denser bone regeneration. To date, divergent results 
that ranged from the significant enhancement of bone formation [142] to a 
limited or null effect of platelet concentrates [143], have been reported. 
b. Orthopedics and sports medicine 
Platelet concentrates have significant potential in the treatment of pathologic 
conditions of cartilage, tendon, ligament and bone including elbow, Achilles and 
patellar tendinopathies, rotator cuff injuries, fractures and their complications 
(delay consolidation and nonunion), anterior cruciate ligament injury and total 
joint arthroplasty. Clinical benefit of platelet concentrates in this medical field 
remains controversial, since their application in trauma and orthopedic 
procedures still lacks the support of randomized controlled clinical trials [144, 
145]. Therefore, additional studies with higher levels of evidence are required to 
support the use of this technology in routing clinical care of this area. 
c. Skin lesions, esthetic and plastic surgery 
Chronic wounds can be classified into three categories: venous, diabetic and 
pressure ulcers, and one of the most common complications of diabetes in the 
lower extremity is the diabetic foot ulcer. Several clinical studies treating small-
sized non healing diabetic ulcers with platelet concentrate are available, 
however controversies exist in the literature regarding the added benefit of this 
technology. Some authors [146-148] found that platelet concentrates had 
improved healing rates over standard care, while others [149, 150] showed no 
major difference in healing outcome of leg ulcers. Kazakos et al. [151] reported 
evidence of effectiveness of platelet concentrates for the treatment not only of 
chronic or non-healing wounds, but also for the management of acute trauma 
lesions. For large, deep ulcers a combination of platelet concentrates with skin 
grafting may be required. 
Platelet concentrates have also been used as an adjuvant in cosmetic surgery, 
and more specifically, in facial plastic surgery. Man et al. [152] reported positive 
results in cosmetic surgeries, Adler and Kent [153] in facelift surgeries, Abuzeni 
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and Alexander [154] in cosmetic dermal fat grafts, and Schade et al. [155] in 
skin grafts. Platelet concentrates have been used as filler in scar management 
[156-158], while in the treatment of burns their relevance remains unclear [159]. 
Recently, the application of autologous platelet concentrates has emerged as a 
new treatment modality in a wide range of dermatological indications ranging 
from hair restoration to acne scarring. In patients receiving platelet 
concentrate’s subcutaneous injection alone [160, 161] or previous hair implants 
[162] a significant increase on the hair density, transplanted follicular and new 
hair growth were detected. Positive effects were also observed In skin 
rejuvenation [163]. More often platelet concentrates are mixed with adipose 
tissue in procedures requiring autologous fat transfer, as breast fat graft or 
reconstruction and abdominoplasty, but the value of their use in this field 
remains unclear [164]. 
d. Other medical fields 
Another interesting application of platelet concentrates is in ophthalmology field, 
where the development of autologous eye-drops can be used in the treatment 
of many eye disorders (i.e. symptomatic dry eye, corneal ulcers) with positive 
effects observed [165, 166]. In addition, the use of this technology in peripheral 
nerve regeneration in rats [167-169] and in perianal fistula [170] has been 
evaluated. 
 
4. Tissue engineering 
End-stage organ failure and tissue loss or damage due to aging or pathological 
conditions is one of most devastating problem in medicine, since this incurs a 
human health care cost and work days lost [171]. Unfortunately, organ and 
tissue transplantation are imperfect solutions as they are limited by a number of 
factors, including the discrepancy between the available organs and the number 
of patients needing transplants, the lifelong immunosuppresion regimens 
required for transplantation recipients associated also with the increased risk of 
infection, disease transmission, tumor development, donor site morbidity, and 
unwanted side effects [172]. Additionally, the replacement with mechanical 
devices (i.e. joints and heart valves) or artificial organs is also limited by an 
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increased risk of infection, thromboembolism and finite durability [173]. 
Recently, a new alternative therapy has become available to clinicians, called 
tissue engineering (also known as regenerative medicine). Tissue engineering, 
an emerging field in biomedical sciences, has been described as “an 
interdisciplinary field that applies the principles of engineering and the life 
sciences toward the development of biological substitutes that restore, maintain, 
or improve tissue function” [171] in order to “replace diseased living tissue with 
living tissue that is designed and constructed to meet the need of each 
individual patient” [174]. Tissue engineering concept dates back to 1933 when 
Bisceglie [175] encased mouse tumor cells in a polymer membrane and placed 
them in the abdominal cavity of a pig, showing that cells were not killed by the 
immune system. In 1975, Chick and colleagues [176] reported that pancreatic-
islet cells encapsulated in semipermeable membranes improved glucose control 
in diabetes, while by the early 1980s other studies attempted the replacement of 
the skin with techniques consisting of fibroblasts cells seeded onto collagen 
scaffold to guide regeneration, which are currently used in clinical practice 
[177]. The primary goal of tissue engineering is to restore the function by means 
of the delivery of living elements that integrate into the patient (Figure 12) [174]. 
 
 
Figure 12. Tissue engineering process. Adapted from Vacanti and Langer, 
Lancet 1999;354:s32-s34. 
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Currently, tissue engineering requires three essential elements: a cellular 
component able to give rise to new structural tissue, a biocompatible and 
mechanically stable matrix scaffold to provide a substrate for cell attachment, 
proliferation and differentiation, and a bioactive component consisting of growth 
and differentiation factors to guide the proper development of the cellular 
component [178]. Three basic approaches have evolved over the last few years 
in tissue engineering to form new tissues. The first strategy is factor based and 
stimulates endogenous cells to induce neo-tissue formation via delivery of 
biological factors that promote cell migration, proliferation and differentiation of 
desired cell type from the surrounding tissues [179]. The second one is a cell 
based approach that involves semipermeable membrane encapsulated cells 
transplantation to augment limited biochemical functions of a tissue or organ 
[180]. The cellular component should consist of healthy, viable cells that are 
accessible, manipulable, and nonimmunogenic. The matrix based therapy is the 
most widely used now, and in this third strategy cells are placed on or within 
matrices in order to create new tissues capable to integrate with the host one, 
thus replacing all the functions of deficient tissue [181]. The carrier component 
has a dual role, acting as both a delivery vehicle and a matrix scaffold. The 
injection of cells alone and the use of cells transplanted on matrices are the 
most common, since isolated cells or cell substitutes avoid potential surgical 
complication and allow cell manipulation (such as gene therapy) before injection 
or infusion, although the possibility of rejection or loss of function [171]. 
4.1. Essential components 
The three essential elements for tissue engineering are scaffold, cells and in 
vitro cell culture system. 
a. Scaffolds for tissue engineering 
Biomaterials represent a way to enhance the in vivo efficacy of growth factors 
by facilitating the release of these bioactive molecules over an extended time 
period incorporating them into a polymer carrier. Initially, scaffolds used for 
tissue engineering were derived from surgical materials, but it is desirable that 
the scaffolding biomaterial can be degraded as cells go through the supportive 
extracellular matrix (ECM) forming process [182]. Scaffolds function as an 
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artificial ECM for cells, mimicking the functional and mechanical properties of 
the native extracellular matrix [183], and can be engineered to deliver growth 
factors, signals and cells or to direct the three-dimensional cell orientation. 
Biomaterials facilitate cells proliferation, differentiation and confinement to the 
desired destination in the body, and define a three-dimensional space guiding 
the new tissue generation with appropriate structure and function [184]. Delivery 
systems have been designed in a variety of geometries and configurations (i.e. 
reservoirs, matrices) and are produced from diverse types of natural materials 
such as collagen, fibrin, hydroxyapatite, glycosaminoglycans, or alginate, [174] 
and synthetic polymers (degradable, non-degradable) such as polyglycolic 
acids (PGA), polylactic acid (PLA), copolymers of glycolic and lactic acids, 
polyurethanes, polyhydroxybutyrate (PH4B), polyanhydrides and polyortho 
esters. Natural materials may closely mimic the native cellular environment as 
they are often extracellular matrix components for cells, and possess natural 
interactive properties like cell adhesiveness, while synthetic materials allow for 
a better control material properties, including strength, degradation time, 
porosity and microstructure. Hydrogels such as pluronic F-127 (a copolymer of 
70% ethylene oxide and 30% propylene oxide) are based on water soluble 
components and are a class of biomaterials with a great scaffolding potential in 
many tissue engineering applications [185]. The polymer’s chemical 
modification or its coating can improve cell attachment and, additionally, growth 
factors can be incorporated into the matrix. Ideal biomaterials should possess 
good mechanical characteristics and defined shapes and sizes, in order to 
maintain the polymers’ structure during new tissue formation, and must be 
biocompatible and bioadsorbable, nonimmunogenic, support cell growth, and be 
able to induce angiogenesis to promote cellular interaction and new tissue 
development [174]. Biodegradable and bioresorbable biomaterials elude the 
inflammatory complication of foreign body reactions deriving from their long-
term presence inside the body [186]. The scaffold degradation is controlled by 
different physical and chemical parameters changes, in order that the non-toxic 
degradation products remain within tolerable limit and are removed from the 
body through normal metabolic pathways [187]. 
b. Cells for tissue engineering 
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Another important consideration in tissue engineering is the cell source and the 
ability to control cell proliferation and differentiation. Cells can be harvested 
from numerous sources, including primary tissue and cell lines, and primary 
cells derived from patient’s own healthy tissues (autologous cells) are the first 
obvious choice, since they avoid the risk of adverse host response and disease 
transmission [188]. In most cases, these cells are however not readily available 
in sufficient quantities for immediate use, therefore primary cells derived from 
normal donors of the same (allogenic cells) or different species (xenogenic and 
syngeneic cells) are available. The latter offer the advantage of 
cryopreservation, but disease transmission and rejection by the host’s immune 
system have to be considered [188]. Ideally, cells should be nonimmunogenic, 
highly proliferative, easy to harvest, and capable to differentiate into the 
appropriate cell type [189]. However, certain cell types poorly proliferate in 
culture or not at all. For this reason, stem cells source, more rapidly proliferating 
and giving rise to a variety of cell types in the body under appropriate culturing 
conditions, provides probably the most promising alternative source for tissue 
engineering to solve the cell-source difficulty [190]. The first step in tissue 
engineering is the isolation and propagation of cells to increase their number 
and reach a large cell population, but this multiplication process may led to cell 
characters lost by a process of dedifferentiation [191]. Therefore, the second 
step aims to induce cell differentiation by means of novel cell carriers and 
matrices, thus allowing cells tissue specific features expression [192]. Also, cell 
anchorage to substrates [193], controlled growth factors deliver matrices [179], 
culture medium composition and media electrolyte concentrations [194] have 
shown to play a role in cell proliferation, differentiation and new tissue 
formation. The use of cell-matrix constructs involves either an open or a closed 
system. An open system consists of in vitro culture of isolated cells, which are 
seeded onto a synthetic or natural scaffold and then the cell-matrix construct is 
implanted into the host after an appropriate cultivation time (Figure 12). On the 
contrary, in a closed system cells are isolated from the body by a permeable 
membrane, allowing exchange of nutrients and waste, but protecting the cells 
from the immune response [171]. 
c. Cell culture systems for tissue engineering 
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Once the scaffold material and the cell source are selected, and cells undergo a 
differentiation process, it becomes necessary to develop more advanced 
procedures for growing cells in large quantities, and for the synthesis of 
extracellular matrix proteins and neogenesis of tissue structures. The most 
widely used culturing technique in tissue engineering is static culturing, but this 
system is often characterized by non-homogeneous cell distribution on the 
scaffold surfaces, that results in an inhomogeneous distribution of the in vitro 
generated extracellular matrix [195]. Several novel approaches such as 
continuous perfusion culture systems, consisting basically on growth chambers, 
have been developed in order to overcome this limitation [196]. These systems, 
so-called bioreactors, are equipped with stirrers and sensors that regulate flow 
and mixing within them, in order to set the appropriate amount of nutrients, 
oxygen, gases, metabolites, regulatory molecules, and waste products, 
essential for the control of the size and structure of the forming tissue and also 
for the prevention of deleterious effects on cell viability and function [197]. 
Furthermore, bioreactors, can provide mechanical regulatory signals (i.e. 
directly applied compression) to stimulate specific biomolecules cells production 
[174]. 
4.2. Mesenchymal stem cells 
Stem cell based therapies that integrate tissue-engineering technologies and 
biomaterials, are fundamental pillars of the science of regenerative medicine for 
the replacement or function restoration of damaged tissues and organs. 
Consequently, the choice of the right stem cell is fundamental for obtaining 
favorable results in tissue engineering. In the last decades, the use of adult 
mesenchymal stem cells (MSCs) in regenerative surgical procedures is steadily 
growing. Mesenchymal stem cells are non-hematopoietic, stromal cells that 
have the potential to differentiate into diverse tissues, including bone, cartilage, 
adipose tissue, tendon, muscle and other tissues of mesenchymal origin, and 
possess also the ability to generate cell types specific for these tissues, like 
chondrocytes, osteoblasts, adipocytes, fibroblasts and marrow stroma (Figure 
13). In the human body MSCs function seems to be a reserve of reparative cells 
with no tissue specific characteristics, but responsive to different signals, 
including tissue damage (such as trauma, fracture, inflammation, necrosis and 
Introduction 
 
37 
 
tumors) [198], chemotaxis [199] and the local microenvironment [200], that can 
direct the cell to mobilize and differentiate into specific cell lines. 
 
Figure 13. MSCs multilineage differentiation potential. Adapted from Caplan 
and Bruder, Trends Mol Med 2001;7:259-264. 
Additionally, MSCs can be easily isolated and expanded in the laboratory under 
standard culture condition, and there are no limitations to their practical use 
related to ethical or religious considerations. The MSCs proliferation and 
differentiation abilities, and the multipotency have suggested them to be 
potential for therapeutic application in regenerative medicine. Originally, such 
adult stem cells have been discovered and characterized by Friedenstein et al. 
[201] in the bone marrow and stroma (BMSCs) of spleen and thymus, but MSCs 
reside in a multitude of tissues, including cartilage, periostium, synovium, 
synovial fluid, muscle, tendons, adipose tissue, placenta and umbilical blood 
[202]. Mesenchymal stem cells have been harvested since long from bone 
marrow for clinical use, since aspirate of this tissue is considered to be the most 
accessible and enriched source of MSCs. However, due to its procurement 
limitations, in the last few years subcutaneous adipose tissue is being 
considered a convenient alternative source of multipotent adult stem cells, since 
it exists in large quantities in our body, it contains a large number of progenitors 
and it can be collected under local anesthesia with lower donor site morbidity 
[203]. Several in vitro studies have shown the similarity between human ASCs 
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(hASCs) and BMSCs regarding their cellular phenotype, growth kinetics, cell 
senescence and differentiation efficiency [204]. These mesenchymal stem cells 
possess the ability in vitro to self-maintain and to differentiate towards cells of 
osteogenic [205], chondrogenic [206], adipogenic [205], myogenic [207] and 
neurogenic lineage [208]. Based on the regenerative and immunomodulatory 
features of hASCs, they might become useful tools for cell-mediated therapy 
[203]. hASCs promote tissue regeneration by secreting multiple cytokines and 
growth factors, including insulin-like growth factor-1 (IGF-1), basic fibroblast 
growth factor (bFGF), hepatocyte growth factor (HGF), transforming growth 
factor beta 1 (TGF-β1), platelet-derived growth factor (PDGF) and the pro-
angiogenic vascular endothelial growth factor (VEGF), that stimulate the 
recovery of damaged tissue in a paracrine manner [209]. This mechanism is 
due to the recruitment of endogenous stem cells to the site and the promotion of 
their differentiation toward specific lineages. Due to these biological 
characteristics, adipose tissue, previously discarded, has recently become an 
invaluable stem cell source for clinical application [209]. 
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Platelet-derived growth factors in recent years assumed a growing importance 
in promoting wound healing and tissue regeneration in a wide range of 
disciplines, including oral, orthopedic and reconstructive surgery. Though, 
several aspects of their biological activity are still unclear. 
The purpose of the present study was to gain more insight regarding the 
biological effect of these molecules on soft and hard tissue healing. 
The effect of an activated platelet concentrate (Plasma Rich in Growth Factors - 
PRGF) on both progenitors and differentiated cells was investigated in terms of 
key cellular functions associated with tissue repair, i.e. cell vitality, growth, and 
osteo-differentiation. The in vitro model developed consisted of a human 
primary cell population derived from the fat tissue, known as adipose-derived 
stem cells (hASCs), and two human terminally differentiated cell lineages 
obtained from bone and derma, that is osteoblasts (hObs) and dermal 
fibroblasts (hDFs), respectively, cultured in the presence of PRGF as substitute 
for fetal bovine serum. The proliferation effect was assessed by means of 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) test and cell 
count, while the osteo-inductive ability was evaluated with the alkaline 
phosphatase (ALP) assay- enzymatic activity. 
The clinical benefit of platelet concentrates as reported in the scientific literature 
is still controversial, especially regarding bone healing and repair. Therefore, 
the effect of the combination of a bone graft substitute with PRGF in enhancing 
bone density was evaluated in a rabbit animal model by means of histological 
and histomorphometric analysis. 
These models may in the future allow for the in vitro bioactivity characterization 
of a patient’s platelet concentrate, so as to determine the different individual 
response to treatment with autologous growth factors, in order to previse the 
effectiveness of a regenerative therapy. 
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1. IN VITRO STUDY 
1.1. Tissues 
Cells used in the in vitro study derived from plastic and orthopedic surgery 
procedures’ discarded tissues obtained from healthy donors after their written 
consent and Institutional Review Board (IRB) approval (IRCCS Galeazzi 
Orthopedic Institute PQ 7.5.125, version 3, 14.05.2012). All patients were in 
general good health without any systemic complication (ASA I-II according to 
the American Society of Anesthesiologists classification) and older than 18 
years. 
1.2. Isolation, characterization and culture of cells 
 
a. Human adipose-derived stem cells (hASCs) 
 
Isolation 
Human adipose-derived stem cells were isolated by liposuction of 15-40ml 
(28.3±12.6ml) subcutaneous-adipose tissue of 3 female patients (age 22-35 
years (mean 29±6.5 years), BMI < 30 Kg/m2, no metabolic disease) as 
previously described [210]. Briefly, after digestion at 37°C with 0.075% type I 
collagenase (250 U/mg; Worthington, Lakewood, N.J., USA) for 30 minutes, the 
stromal vascular fraction (SVF) was separated by centrifugation (1200g for 10 
minutes), filtered and hASCs were plated (105 cells/cm2) in DMEM (Sigma-
Aldrich, Milan, Italy) supplemented with 10% fetal bovine serum (FBS), 50U/ml 
penicillin, 50mg/ml streptomycin and 2mM L-glutamine (Sigma-Aldrich) (control 
medium, CTRL). 
Proliferation 
Plastic culture flasks-adherent hASCs were selected during subsequent 
passages. The fibroblast-like morphology displayed by the isolated cells was 
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checked by phase-contrast microscopy and the doubling time was calculated as 
(t2-t1)×ln2/ln(N/N0), where N is the number of counted cells and N0 represents 
the number of plated ones. 
MTT cell viability assay 
Cell viability was tested by means of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) test. 3x104 hASCs/cm2 were plated in 96-
well plates, and monitored at day 1 and 7. Then 100µl of MTT (Sigma-Aldrich) 
(final concentration 0.5mg/ml in DMEM) were added and cells were maintained 
for 4 additional hours at 37°C. Formazan precipitat es were solubilized by 100% 
DMSO (dimethyl-sulphoxide, Sigma-Aldrich) and absorbance was read at 
570nm in a Wallac Victor II plate reader (Perkin Elmer Western Europe, Monza, 
Italy). 
Fibroblast-colony-forming unit assay (CFU-F) 
hASCs, were plated in DMEM supplemented with 20% FBS, 50U/ml penicillin, 
50µg/ml streptomycin, and 2mM L-glutamine, in 6-well plates by serial dilution 
starting from 1000 cells/well. After 6 days the medium was replaced and, at day 
14 cells were washed, fixed in 100% methanol and stained with 0.5% crystal 
violet (Fluka, Buchs, Switzerland). The colony-forming unit-fibroblast (CFU-F) 
frequency was established by counting individual colonies (of at least 20 cells) 
compared to the number of seeded cells. 
Flow cytometry analysis 
hASCs (3x105) in PBS with 1% FBS/0.1% NaN3 per sample were incubated for 
30 minutes on ice with monoclonal antibodies raised against CD14, CD31 
CD34, CD73, CD90, and CD105 (Ancell, Bayport, MN). Specific binding was 
revealed by either streptavidin-PE- or fluorescein isothiocyanate-conjugated 
sheep anti-mouse antibody. Samples were characterized immunophenotypically 
by FACS Calibur flow cytometer (BD Biosciences Europe, Erembodegem, 
Belgium) and data were analyzed using CellQuest software (BD Biosciences 
Europe). Cells were CD73, CD90, CD105 and CD271 positive and CD14 and 
CD45 negative. 
Osteogenic differentiation 
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7,75x103 hASCs/cm2 at 4th and 7th passages were maintained for 14 days in 
either control (CTRL) or osteogenic medium (OSTEO, DMEM, 10% FBS, 10nM 
dexamethasone, 10mM glycerol-2-phosphate, 150µM L-ascorbic acid-2- 
phosphate, 10nM cholecalciferol, Sigma-Aldrich). 
To evaluate alkaline phosphatase (ALP) enzymatic activity, hASCs were lysed 
in 50µl of 0.1% Triton X-100 and incubated at 37°C with 10mM p-
nitrophenylphosphate dissolved in 100mM diethanolamine and 0.5mM MgCl2, 
pH 10.5. Samples were read at 405nm and ALP activity was standardized 
respect to the sample protein concentration determined by BCA Protein Assay 
(Pierce Biotechnology, Rockford, IL). 
To determine collagen production, cells were stained with 0.1% (w/v) Sirius Red 
F3BA in saturated picric acid (Sigma-Aldrich) for 1 hour at room temperature, 
and then the samples were extracted with 0.1M NaOH for 5 minutes and 
absorbance was read at 550nm [211]. Standard curve of known concentration 
of calf skin type I collagen (Sigma-Aldrich) was used to determine the 
concentration of secreted collagen. 
Extracellular matrix (ECM) calcification was determined on fixed hASCs stained 
by 40mM Alizarin Red-S (AR-S, pH 4.1; Fluka). Mineral deposition was 
quantified by incubating the stained sample with 10% w/v cetylpyridinium 
chloride (CPC; Sigma-Aldrich) in 0.1M phosphate buffer (pH 7.0) for 15 minutes 
to extract AR-S. Absorbance was read at 550nm with Wallac Victor II plate 
reader [212]. 
Adipogenic differentiation 
hASCs were induced to differentiate towards the adipogenic lineage as 
previously described with some modifications [213]. Briefly, 1.5x104 hASCs /cm2 
were plated and cultured in control medium supplemented with 1µM 
dexamethasone, 10µg/ml insulin, 500µM 3-isobutyl-1-methylxanthine, and 
200µM indomethacin (Sigma-Aldrich). 14 days later, cells were fixed in 10% 
neutral buffered formalin for 1 hour and stained by fresh Oil Red O solution 
(20mg/mL [w/v] Oil Red O in 60% isopropanol) for 15 minutes. Lipid vacuoles 
were quantified by extraction with 200µl of 100% isopropanol for 10 minutes 
and reading the absorbance of 50µl at 490nm with Wallac Victor II plate reader. 
Chondrongenic differentiation 
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5x105 hASCs were cultured in micromasses in chondrogenic medium (DMEM 
supplemented with 1% FBS, 100nM dexamethasone, 110mg/l sodium pyruvate, 
150µM L-ascorbic acid-2- 9 phosphate, 1x insulin-transferrin selenium (ITS) and 
10ng/ml TGF-β1) for 21 days. Glycosaminoglycans (GAGs) production was 
assessed by dimethylmethylene blue (DMMB) assay as previously described 
[214, 215]. Briefly, micromasses were digested at 56°C overnight by 100 µl of 
50µg/ml proteinase K in 100mM K2HPO4 (pH 8.0). After 10 minutes at 90°C to 
inactivate the enzyme, the samples were spun at 14000g for 10 minutes and 
each supernatant was collected for GAGs. Samples were then incubated at 
room temperature in 40mM glycine/NaCl (pH 3) with 16mg/ml DMMB and the 
absorbance was read at 500nm with the Wallac Victor II plate reader. The 
amount of GAGs was determined respect to known concentrations of 
chondroitin sulfate (Sigma-Aldrich). 
b. Human osteoblasts (hObs) 
 
Isolation 
Human osteoblasts were isolated from cortical bone of two male patients (age 
43 and 57 years, with no metabolic disease) undergoing osteotomy. Bone 
fragments were digested for 60 minutes with collagenase type II (0.003%) at 
37°C and hObs were plated in basal medium (DMEM) su pplemented with 10% 
FBS, 50U/ml penicillin, 50mg/ml streptomycin and 2mM L-glutamine. Plastic 
culture flasks-adherent hObs were selected during culture. 
c. Human dermal fibroblasts (hDFs) 
 
Isolation 
Human dermal fibroblasts were obtained from a 46 years healthy female patient 
undergoing abdominoplastic surgery. The tissue was digested for 6 hours in 
DMEM and 0.1% collagenase I at 37°C and hDFs-1 were  separated by 
centrifugation (1200g for 10 minutes), filtered and plated (105 cells/cm2) in 
complete medium. 
Proliferation 
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The fibroblast-like morphology displayed by the isolated cells was checked by 
phase-contrast microscopy and the doubling time was calculated as (t2-
t1)×ln2/ln(N/N0), where N is the number of counted cells and N0 represents the 
number of plated ones. 
MTT cell viability assay 
Cell viability was tested by means of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) test. 3x104 hASCs/cm2 were plated in 96-
well plates, and monitored at day 1 and 7. Then 100µl of MTT (Sigma-Aldrich) 
(final concentration 0.5mg/ml in DMEM) were added and cells were maintained 
for 4 additional hours at 37°C. Formazan precipitat es were solubilized by 100% 
DMSO (dimethyl-sulphoxide, Sigma-Aldrich) and absorbance was read at 
570nm in a Wallac Victor II plate reader (Perkin Elmer Western Europe, Monza, 
Italy). 
Osteogenic differentiation 
1,5x104 hDFs/cm2 at 4th passages were maintained for 14 days in either control 
(CTRL) or osteogenic medium (OSTEO, DMEM, 10% FBS, 10nM 
dexamethasone, 10mM glycerol-2-phosphate, 150µM L-ascorbic acid-2- 
phosphate, 10nM cholecalciferol, Sigma-Aldrich). 
To evaluate alkaline phosphatase (ALP) enzymatic activity, hDFs were lysed in 
50µl of 0.1% Triton X-100 and incubated at 37°C wit h 10mM p-
nitrophenylphosphate dissolved in 100mM diethanolamine and 0.5mM MgCl2, 
pH 10.5. Samples were read at 405nm and ALP activity was standardized 
respect to the sample protein concentration determined by BCA Protein Assay 
(Pierce Biotechnology, Rockford, IL). 
To determine collagen production, cells were stained with 0.1% (w/v) Sirius Red 
F3BA in saturated picric acid (Sigma-Aldrich) for 1 hour at room temperature, 
and then the samples were extracted with 0.1M NaOH for 5 minutes and 
absorbance was read at 550nm [211]. Standard curve of known concentration 
of calf skin type I collagen (Sigma-Aldrich) was used to determine the 
concentration of secreted collagen. 
Extracellular matrix (ECM) calcification was determined on fixed hDFs stained 
by 40mM Alizarin Red-S (AR-S, pH 4.1; Fluka). Mineral deposition was 
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quantified by incubating the stained sample with 10% w/v cetylpyridinium 
chloride (CPC; Sigma-Aldrich) in 0.1M phosphate buffer (pH 7.0) for 15 minutes 
to extract AR-S. Absorbance was read at 550nm with Wallac Victor II plate 
reader. 
Adipogenic differentiation 
hDFs were induced to differentiate towards the adipogenic lineage as previously 
described with some modifications [213]. Briefly, 2x104 hDFs /cm2 were plated 
and cultured in control medium supplemented with 1µM dexamethasone, 
10µg/ml insulin, 500µM 3-isobutyl-1-methylxanthine, and 200µM indomethacin 
(Sigma-Aldrich). 14 days later, cells were fixed in 10% neutral buffered formalin 
for 1 hour and stained by fresh Oil Red O solution (20mg/mL [w/v] Oil Red O in 
60% isopropanol) for 15 minutes. Lipid vacuoles were quantified by extraction 
with 200µl of 100% isopropanol for 10 minutes and reading the absorbance of 
50µl at 490nm with Wallac Victor II plate reader. 
All cells used for the in vitro study were maintained in a humidified atmosphere 
at 37°C with 5% CO 2 until confluence and medium changed every 2-3 days. 
1.3. Blood collection and preparation of the activated platelet 
concentrate 
The acellular plasma of a platelet concentrate (PC) was obtained using a 
manual protocol performed by an experienced technician. Peripheral blood from 
five young healthy volunteer donors (four females and one male, age 23-29 
years (26.2±2.6), in general good health and older than 18 years) was collected 
in 9-ml tubes (BTI blood collecting tubes®) with 3.8% sodium citrate (m/v) as 
anticoagulant and centrifuged at 580g for 8 minutes at room temperature in a 
standard laboratory centrifuge (Sigma 3-16K, Sciquip). Blood cells stratified 
according to a density gradient into three distinct layers: the bottom fraction 
contained erythrocytes and the top fraction contained platelets. The two 
fractions were separated by the whitish buffy coat layer, which contained most 
of the leukocytes. The 2ml plasma fraction just above the buffy coat, containing 
the highest platelets concentration, was identified as Plasma Rich in Growth 
Factors (PRGF) and collected. The upper part of the acellular plasma just 
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above the PRGF layer, presenting the lowest platelets concentration was 
identified as Plasma Poor in Growth Factors (PPGF) and discarded (Figure 14). 
Platelets count was performed with a hematology analyzer (Sysmex, XE-2100, 
Norderstedt, Germany). After PRGF activation with a CaCl2 solution, (PRGF-
Activator®, BTI Biotechnology Institute, S.L., Vitoria, Spain) it was immediately 
aliquoted and stored at -80°C until its use. After being thawed at 37°C in a 
water bath for few minutes, it was incubated at 37°C for 30 minutes, triggering 
thereby platelet activation and growth factors release, and then used as 
supplement to the culture medium. 
 
Figure 14. Plasma Rich in Growth Factors protocol. a) Blood collection and 
processing. b) Activated platelet concentrate’s production. 
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1.4. Cell proliferation assay 
From passage 1 to 3 in culture, cells were detached with 0.5% trypsin/ 0.2% 
EDTA and plated at a density of 8×103cells/cm2 in 6-well tissue-culture plates in 
control medium. After one day cells were starved for 24 hours to allow cell cycle 
synchronization, then culture medium was replaced by medium supplemented 
with either 5% PRGF or 10% FBS (CTRL). At day 4, 8, 12, cells were detached 
with 0.5% trypsin/ 0.2% EDTA (Sigma-Aldrich) and counted in a Burker 
chamber considering also trypan blue exclusion. All the experiments were 
performed in duplicates. 
1.5. Cell viability assay 
Cells derived from the counting assays at day 4, were used for vitality 
evaluation. From passage 3 to 5 cells were plated at a density of 1,5×104 
cells/cm2 in 96-well tissue-culture plates in the presence of either 5% PRGF or 
10% FBS. After 5 and 12 days in culture, 100µl of 0.5mg/ml MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich) was 
added and incubated for 4 hours at 37°C. The formaz an precipitate was 
solubilized with 100% dimethylsulphoxide (DMSO; Sigma.Aldrich) and the 
absorbance read at 550nm with a Celbio plate reader. All the experiments were 
performed in duplicates. 
1.6. hASC and hOb osteogenic differentiation assay 
hASCs and hObs at 1st and 3rd passages were plated in 24-well tissue-culture 
plates at a density of 7,5×103 cells/cm2 for 7 days and 5×103 cells/cm2 for 14 
days, and let adhere overnight in control medium. After being washed and 
cultured for 24 hours in serum-free medium, either 2.5% PRGF or 10% FBS 
(CTRL) were added. Osteogenic stimuli such as 10nM dexamethasone, 10mM 
glycerol-2-phosphate, 150µM L-ascorbic acid-2-phosphate and 10nM 
cholecalciferol (OSTEO; Sigma-Aldrich) were added to the cell culture medium 
to induce differentiation. Cells were cultured for 7 and 14 days before the 
biochemical analyses, then they were lysed with 50µl of 0.1% Triton X-100. Cell 
lysates were incubated with 1mM p-nitrophenylphosphate in alkaline buffer 
(100mM diethanolamine and 0.5mM MgCl2, pH 10.5) at 37°C. The reaction was 
stopped with 1N NaOH and absorbance read at 405nm with a Wallac Victor II 
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plate reader. Alkaline phosphatase (ALP) assay- enzymatic activity was then 
normalized respect to each sample protein concentration determined by BCA 
protein assay (Pierce Biotechnology, Rockford, Ill., USA). 
1.7. Statistical analysis 
All data are expressed as mean values ± standard error (SE) and statistical 
analysis (unpaired Student’s t-test) was performed by using GraphPad Prism 
5.03 (GraphPad Software, San Diego, Calif., USA). Differences were 
considered significant at p<0.05. 
 
2. ANIMAL STUDY 
2.1. Animals 
For the in vivo study six adult male white New Zealand rabbits 3 months old and 
weighing 3-3.5 kg were used. All animal experiments were performed at the 
animal facility of the Department of Veterinary Medicine, University of Milan in 
accordance with current European Community standards on testing animals 
and for the treatment of laboratory animals (guidelines 86/609/EEC of the 
European Union), and approved by the Italian Ministry of Health (DL 116/92) 
under the Eurostars Project BioBone. The animals were housed in individual 
indoor cages with food and water provision ad libitum. They were clinically 
examined and acclimatized to their environment for 7 days before the 
experiment. Blood harvesting and surgery procedures were carried out by 
veterinary and oral surgeons. 
2.2. Preparation of the activated platelet concentrate 
Five milliliters of blood were collected immediately before surgery via ear 
venipuncture in anticoagulated tubes and centrifuged at 460g for 8 minutes at 
room temperature in a standard laboratory centrifuge. Blood stratified into the 
three typical layers (erythrocytes at the bottom, buffy coat in the middle and 
acellular plasma on top) and the 1ml of plasma just above the buffy coat 
(PRGF) was collected and activated with 10% CaCl2 solution (PRGF-
Activator®, BTI Biotechnology Institute, Vitoria, Spain) at 37°C for few minutes. 
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2.3. Experimental design and surgical procedure 
Defects were randomly divided into 3 groups:  
1) negative control group (sham), in which the defects was left without any graft; 
2) Bio-Oss group, in which the defect was filled only with the bone substitute 
Bio-Oss (particles sized 0.25mm-1mm); 
3) Bio-Oss+PRGF group, in which the defect was filled with Bio-Oss in 
combination with the platelet concentrate PRGF. 
Each group consisted of 4 samples, for a total of 12 defects. 
All experimental procedures were conducted under a clean protocol with the 
use of sterile materials and equipment. General anesthesia was induced with 
subcutaneous (SC) administration of Dexmedetomidina (Dexdomitor®) 
80µg/kg, Ketamina (Ketavet100®) 15mg/kg and Buprenorfina (Temgesic®) 
20µg/kg, and maintained with Lactated Ringer’s solution administered with an 
intravenous catheter placed in the ear’s vein. Each animal received 100% 
oxygen by means of a face mask, throughout the entire surgical procedure until 
complete awakening. After tricotomy and exposure of the proximal tibia, 
bilateral circular critical lesions (8x2mm) were made at the tibial crest using a 
8mm diameter trephine (BTI, Biotechnology Institute, S.L., Vitoria, Spain). The 
defects were randomly divided so that the two sides of each rabbit received a 
different treatment: bone substitute alone (Bio-Oss®, Geistlich Pharma, 
Wolhusen, Switzerland), Bio-Oss+PRGF, no graft (sham -control) (Figure 15). 
For animals receiving the bone substitute in association with PRGF, the 
biomaterial was combined in a ratio 0.5g/ml PRGF. 
 
 
 
 
 
Figure 15. a) Creation of the bone defect. b) Defect filling with bone 
substitute. 
a b 
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After filling of the defects the overlying soft tissues were repositioned and 
sutured with an absorbable 2-0 suture (Ethicon®, Johnson & Johnson). The 
animals were then placed under post-surgical analgesic therapy with 
Buprenorfin (Temgesic®) 15µg/kg BID SC and Meloxicam (Metacam®) 
0,2mg/kg SID SC for 4 days. Antibiotic prophylaxis was also done with 
Enrofloxacin (Baytril® sol. 2,5%) at 10 mg/kg/die SC and animals underwent 
periodical controls by veterinary staff until the end of the experiment (week 8 
post-surgery). Three days after surgery fracture of one leg in a rabbit occurred, 
the animal was euthanized and another rabbit undergoing the same treatment 
(Bio-Oss on one side and Bio-Oss+PRGF on the other side) was used as a 
replacement. 
2.4. Histological and histomorphometric evaluations 
After 8 weeks, each animal was anesthetized by subcutaneous (SC) 
administration of Dexmedetomidina (Dexdomitor®) 80µg/kg, Ketamina 
(Ketavet100®) 15mg/kg and Buprenorfina (Temgesic®) 20µg/kg and then 
euthanized with 0.5ml/Kg EV Tanax. Left and right tibiae were removed from 
each rabbit, dissected free of soft tissue and bone blocks of the surgically 
involved area were explanted using a surgical bur (outer diameter 4mm, inner 
diameter 3.4mm) attached to a slow-speed electrical handpiece, and preserved 
and fixed in 10% neutral-buffered formalin for 48 hours at room temperature. 
Specimens were labeled so that the histologist was not aware of the group 
(treated or control) corresponding to the sample. The block sections were 
decalcified in a formic acid-sodium citrate solution. The solution was changed 
daily until an assay for free calcium in solution was negative (approximately 3 
weeks). The assay for free calcium involved mixing 2ml of the decalcifying 
sample solution with 0.5ml of saturated ammonium oxalate. If a cloudy milky 
precipitate did not form within 10 minutes, decalcification was considered 
complete. After decalcification procedure, samples were rinsed under running 
tap water for 2 hours, and routinely processed through a graded ethanol series 
and embedded in paraffin. Serial sections of 5µm thickness of each specimen 
were prepared, followed by hematoxylin-eosin staining (H-E). Samples were 
evaluated for ascertaining structural details with a light microscope (Olimpus 
BX51, Olympus Corporation, Tokyo, Japan). Histomorphometric analysis on 
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digitalized images was performed by a blinded operator using the Image J 
software (NIH Image-J v.1.45s; US National Institute of Health, Bethesda, MD, 
USA). For the determination of the vital bone content, a x25 magnification was 
used, evaluating the complete section for each case; approximately 7mm2 per 
each sample was examined. The newly formed bone, residual deproteinized 
bone bovine particles, and soft-tissue areas were measured semiautomatically 
and expressed as percentage of the total area. 
2.5. Statistical analysis 
Statistical analysis was performed by using GraphPad Prism 5.03 (GraphPad 
Software, San Diego, Calif., USA). Unpaired Student’s t-test was used to 
compare mean percentage of newly formed bone between groups. All data are 
expressed as mean values ± standard deviation (SD) and differences were 
considered significant at p<0.05. 
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Results 
 
1. IN VITRO STUDY 
1.1. Platelet concentration in PC 
The mean value of whole blood platelet concentration from the 5 volunteer 
donors was 248.14×103 platelets/µl (range 219-291×103 platelets/µl). After 
centrifugation, the mean concentration of platelets in the PRGF was 434.43×103 
platelets/µl (range 289-584×103 platelets/µl), with a mean increase of 1,8% 
(Table 3). 
 
 
 
 
                        PRGF, Plasma Rich in Growth Factors; SD, standard deviation. 
Table 3. Clinical data of the volunteers. 
1.2. Cell proliferation 
A preliminary in vitro study for choosing the ideal PRGF concentration was 
performed. hASCs were incubated for 4, 8, 12 days in medium enriched with 
10% FBS (CTRL) or with 2.5% or 5% platelet concentrate. The percentage of 
increase or decrease of cell number derived from two independent experiments 
performed with PC from one donor, was calculated (Table 4). The highest cell 
count values were obtained when hASCs were cultured in medium 
supplemented with 5% plasma. After 12 days cells showed an increased 
proliferation up to 19.8-fold for PRGF respect to the control. 2.5% platelet 
concentrate induced a lower but comparable to the control cell proliferation. 
Consequently, the following assays were performed with 5% activated platelet 
concentrate as substitute for FBS. 
 
 
Variable number or mean ± SD 
Female/Male 4/1 
Age (years) 26.2 ± 2.6 
Platelets of blood (103/µl) 248.14 ± 31.13 
Platelets of PRGF (103/µl) 434.43 ± 108.97 
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  4 days  8 days  12 days 
 PC 
(%) 2.5 5  2.5 5  2.5 5 
PRGF  110 336  -15 1138  -78 2364 
PC, platelet concentrate; PRGF, Plasma Rich in Growth Factors 
Table 4. Effect of different concentrations of PC on human adipose-
derived stem cells proliferation, expressed as percentage as compared to 
baseline. 
Cell proliferation was demonstrated by the trypan blue dye uptake. At day 4, 
hASCs proliferated faster than in control culture condition (CTRL) medium and 
the number of cells collected after 12 days was about 10 times higher than the 
control, suggesting that these progenitor cells adapted easily to the new micro 
environment (Figure16a). Human osteoblasts grown in the presence of 5% 
PRGF showed a proliferation rate either lower or similar to the CTRL at each 
time point (Figure 16b upper). However, hObs maintained in culture with PRGF 
for 12 days without any detachment, increased their growth by 1.2-fold respect 
to the CTRL (Figure 16b lower). A similar trend was observed for hDFs: at early 
time points cell number did not increase appreciably, while after 12 days of 5% 
PRGF, cell proliferation rate increased 3-fold as compared to the standard 
condition (Figure 16c), with a particularly notable growth peak. The incubation 
with PC determined a non-significant statistical increase between the PRGF 
stimulation and control during 12-day culture period for all of the three cell types 
(P > 0.05). 
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Figure 16. Effect of PRGF on hASCs, on hObs and on hDFs. a) hASC 
proliferation with PRGF. Data are shown as the means ± SE (standard error) of 
three independent experiments performed with platelets concentrate derived 
from blood of three donors. b) Effect of 5% PRGF on human Osteoblast 
proliferation. hOb proliferation analyses were performed either after cell 
detachment every 4 days (upper) or without detaching them (lower). Data are 
shown as means ± standard error (SE) of three independent experiments 
performed with the PRGF of two donors. c) hDFs proliferation after treatment 
with 5% PRGF. Data are shown as means ± SE (standard error) of two 
independent experiments performed with the PRGF from one donor. 
Morphological changes were never induced by PRGF, and phase contrast 
microscopy images after 4 days in culture, revealed a higher number of hASCs, 
hObs and hDFs when cells were grown in the presence of the platelet 
concentrate respect to the standard condition (Figure 17). 
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Figure 17. Representative phase contrast photomicrographs. hASCs, hObs 
and hDFs grown on a tissue culture plate for 4 days in standard condition 
(CTRL) and in media supplemented with 5% PRGF (40x magnification). 
1.3. Cell viability 
PRGF never exhibited cytotoxic effects on all of the three cell types. From MTT 
tests, at day 5, hASC viability was reduced compared to the control, while at 
day 12 it increased confirming that hASCs required more time to adapt to the 
human supplement, although this difference was not statistically significant 
(Figure 18a). hOb vitality improved of 1.8-fold after 12 days, whereas in CTRL 
condition it increased about 1.9-fold (Figure 18b) (P < 0.05). Moreover, hDFs 
grown for 12 days in medium supplemented with platelet-rich plasma achieved 
a 7.8-fold cell viability increase compared to day 5, whereas in CTRL condition 
it just improved of 2.4-fold (Figure 18c). 
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Figure 18. Viability of cells treated with PRGF. a) Evaluation of cell viability 
(MTT test) with 5% PRGF on hASCs. Data are shown as means ± SE of three 
independent experiments performed with platelets concentrate derived from 
blood of three donors. **p < 0.01 treated vs control value. b) Percentage of 
absorbance value of hObs with PC compared with that of each control was 
calculated. Results are expressed as means ± SE (standard error) of three 
independent experiments performed with the PRGF of two donors. Significant 
statistical differences were seen between the PRGF stimulation and untreated 
control during 12-day culture period (P < 0.05). c) hDFs viability after treatment 
with 5% PRGF. Data are shown as means ± SE (standard error) of two 
independent experiments performed with the PRGF from one donor. 
1.4. Inter-donor and cell population-origin variability 
The effect of PRGF from several donors and on different hASC populations was 
also analyzed. The inter-donor variability among platelet concentrates and 
hASC populations was less pronounced at early time points compared to later 
ones, and the marked effect of PRGF, independently of its donor and of the 
responder cells (different hASC populations) was confirmed at a later time point 
(Figure 19). 
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Figure 19. Effect of PRGF from different donors and the same PRGF on 
different cell populations. a) Cell viability (MTT assay) and b) proliferation 
(cell count) of a single hASC population (I) cultured with three PRGF samples 
(D1, D2, D3). c) Viability and d) proliferation of three hASC populations (I, II, III) 
cultured with a PRGF sample. A representative experiment for each condition is 
shown. 
1.5. hASC and hOb osteogenic differentiation 
Alkaline phosphatase activity was determined in two hASC populations (ASC-I 
and ASC-II) osteo-differentiated for 7 and 14 days in the presence of 2.5% 
PRGF. After 7 days the enzymatic activity considerably increased when platelet 
concentrate was present (Figure 20a). Cells cultured with PRGF exhibited 
higher levels of this marker compared to those cultured with FBS. In addition, in 
the absence of osteo-differentiative stimuli ALP activity was also induced. At 
day 14 the effect was reduced respect to day 7, but still present (Figure 20b). 
ALP activity was also determined in osteoblasts osteo-induced for both 7 and 
14 days in the presence of 2.5% PRGF. As shown in Figure 20c, osteoblasts 
that received PRGF and differentiation medium (OSTEO) slowly increased their 
ALP activity, with an increase at day 14 (about 4-fold respect to day 7) and the 
presence of PRGF did not further induced this enzyme. Instead, hObs treated 
with FBS and OSTEO medium showed the greatest ALP activity increase at day 
14. 
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Figure 20. Osteogenic differentiation. a, b) ALP activity of two hASC 
populations (I, II) osteo-induced in the presence of 2,5% PRGF for 7 and 14 
days, respectively. A single experiment for each condition is shown. (c) 
Differentiation assessment of hObs in the presence of 2,5% PRGF after 7 and 
14 days. Data are shown as the means ± SE (standard error) of two 
independent experiments. ALP activity is expressed as U/mg proteins. 
In parallel, hASC calcium deposition tested by alizarin red staining (ARS) was 
also increased after 14 days of cell differentiation by the presence of PRGF 
(Figure 21). 
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Figure 21. Calcium deposition. Alizarin Red Staining was used to measure 
calcium deposition after 14 days. Representative images of treated hASCs in 
plates are shown after staining. A single experiment for each condition is 
shown. 
 
2. ANIMAL STUDY 
2.1. Histological analysis 
All specimens showed vital new bone formation. Samples left healing with no 
biomaterial graft (sham control) showed the presence of compact bone tissue, 
which lies in between the marrow tissue, parallel to portions of reparative tissue. 
Near to the latter, some osteoblasts were detectable indicating a regular bone 
healing process still ongoing (Figure 22). In defects treated with Bio-Oss alone 
(Bio-Oss group), granules of the biomaterial in contact with compact bone 
tissue that surrounded the granules were evident (Figure 23). This scenario is 
compatible with standard bone regenerative process. In the third group (Bio-
Oss+PRGF) where Bio-Oss was used in association with PRGF, the biomaterial 
was evident in contact with compact bone tissue (Figure 24). Furthermore, in 
the region close to the biomaterial some osteoblasts were visible, indicating an 
ongoing bone formation process, a scenario compatible with standard bone 
healing process. 
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Figure 22. Sham control. Photomicrographs of group 1 after a healing period 
of 8 weeks revealing a trabecula of compact bone tissue (arrow) which lies in 
the myeloid tissue, parallel to a portion of reparative tissue (asterisk). Near to 
the latter some osteoblasts (arrow head) are visible (H-E staining). 
 
Figure 23. Bio-Oss. Photomicrographs of group 2 after a healing period of 8 
weeks revealing the biomaterial (asterisk) in contact with compact bone tissue 
(arrow) (H-E staining). 
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Figure 24. Bio-Oss + PRGF. Photomicrographs of group 3 after a healing 
period of 8 weeks revealing the biomaterial (asterisk) in contact with compact 
bone tissue (arrow). In the region close to the biomaterial some osteoblasts are 
visible (arrow head) (H-E staining). 
2.2. Histomorphometric analysis 
Data derived from histomorphometric analysis showed that after 8 weeks the 
mean percentage of newly formed bone was 18.7±4.0% in the control group 
and 18.4±5.4% in the Bio-Oss one, up to 26.0±2.2% in the Bio-Oss+PRGF 
group (Figure 25). The differences between groups were not statistically 
significant (p = 0.32 sham vs Bio-Oss; p = 0.17 sham vs Bio-Oss+PRGF; p = 
0.09 Bio-Oss vs Bio-Oss+PRGF). 
 
Figure 25. Newly formed bone. Mean percentage values ± standard 
deviations (SD) of newly formed bone of each experimental group. 
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Discussion 
 
Platelets are very important in the tissue healing process since they arrive 
quickly at the injured site beginning the coagulation cascade, and they release 
multiple cytokines and growth factors involved in wound healing [216]. Growth 
factors are thought to contribute to bone regeneration and increased 
vascularity, and play an important role in both soft tissue and bone repair 
process [217]. Many of the early phases of both bone and soft tissue reparative 
process, such as infiltration and proliferation of precursor cells, could be 
stimulated by a number of GFs in particular PDGF and TGF-β [91, 218, 219]. 
The use of autologous platelet concentrate has spread in different medical 
conditions for regenerative purpose [87]. Its effects on tissue regeneration have 
been shown in dentistry, oral implantology, orthopaedics, sports medicine, and 
treatment of skin disorders [87]. To date, different techniques to obtain platelet 
concentrates are available, each method leading to preparations that may differ 
in leukocyte and fibrin content, and platelet concentration [134]. Plasma Rich in 
Growth Factors (PRGF) is a modified Pure Platelet-Rich Plasma (P-PRP) 
introduced by Anitua in 1999 [135] and obtained by means of a manual protocol 
[220] from a small volume of patient’s blood and sodium citrate and calcium 
chloride as anticoagulant and activator, respectively. The main difference with 
PRP is that according to the Anitua’s protocol, leukocytes are intentionally 
excluded in order to avoid pro-inflammatory effects of proteases and acid 
hydrolases contained in white blood cells [87]. In addition, as this source of 
growth factors is autologous, there is no risk of immune reaction and infectious 
disease transmission associated with the use of this technology. 
In the present study, it was demonstrated the in vitro ability of PRGF to induce 
proliferation of human adipose-derived stem cells, human osteoblasts and 
human dermal fibroblasts, and osteogenic differentiation of hASCs and hObs, 
all cell types being critical for wound healing of bone and soft tissues [221]. 
Such findings may support the clinical use of PRGF in regeneration procedures. 
Furthermore, the effect of PRGF was compared to control culture condition 
suggesting that a platelet concentrate could be a valid alternative to the serum 
commonly used for cell cultures, although further tests are needed to confirm 
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the biological comparability of platelet concentrate and fetal bovine serum 
(FBS). Mesenchymal stem cells from adipose tissue were used as a cellular 
model knowing their role in angiogenesis, growth factors secretion, 
inflammatory process regulation and differentiation capability [222]. We also 
included fibroblasts, for their important role in tissue repair [221], and 
osteoblasts, fundamental in the bone regeneration process. The longest 
observation time of 12 days was chosen in vitro as the end-point for the 
evaluation of cell proliferation since in vivo, after this period, the wound is 
usually covered with new tissue [46]. In this study cells and blood for the platelet 
concentrate’s preparation were not harvested from the same donors. This 
choice was supported by a previous study reporting that cells grown in the 
presence of both human autologous and heterologous sera, increased their 
proliferation rate compared to standard culture condition [223], and especially to 
the absence of leukocytes from PRGF with a consequent reduced risk of 
immune reaction between the PC cells and the cultured ones. 
To date, little is known about the in vitro effect of platelet concentrates on cell 
function. 
Despite the low number of studies that investigated the effect of platelet 
concentrates on hASCs, the effectiveness of PCs in combination with hASCs on 
cell stimulation and tissue healing has been reported [224]. This was also 
confirmed in our study in which FBS was completely substituted by PC, and 
although culture media have been supplemented with a lower concentration of 
platelet concentrate compared to other studies [96], after a short adaptation 
period, cell viability and proliferation were comparable to the control ones. Most 
in vitro studies on PCs activity reported in the literature have been carried out 
on either animal cell lineages [225-227] or commercialized ones [94, 100, 228-
230], while only few researches used human osteoblast primary cultures [95, 
231-233]. This lack can be partially explained by the relative difficulty of 
obtaining such high-quality lineages and growing them in vitro [234] together 
with the complexity for osteoblasts to express and secrete in culture all the 
essential proteins for in vitro mineralized bone formation [218]. The clinical 
usefulness of platelet concentrates is still controversial especially for bone 
healing and repair. Although several animal and clinical studies have suggested 
that PCs may enhance bone formation [99, 235], a similar number of reports 
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have failed to demonstrate significant benefit [97, 143, 236-238]. Autologous 
bone grafts from intra- and extra-oral donor sites, have been regarded as a gold 
standard in the bony defects regeneration, especially in craniofacial surgery 
[239], but the disadvantages of donor site morbidity and limited possibility of 
harvesting autogenous bone, led to the use of bone substitutes to avoid patient 
discomfort. Currently, several degradable or permanent, mainly 
osteoconductive bone substitutes like tricalcium phosphate or xenogenic 
hydroxyapatite ceramics are available [216]. Some clinical trials suggested that 
the combination of autologous bone graft [132] and bone graft substitutes [240, 
241] with growth factors contained in platelet concentrates may be suitable to 
enhance bone density. Bio-Oss is an inorganic osseous matrix produced after 
elimination of the medullar bovine bone organic components by means of a 
thermal treatment. It is a non-resorbable bone substitute [242, 243] that 
preserves the trabecular architecture and porosity and acts as a 
osteoconductive material. The physical properties of Bio-Oss permit clot 
stabilization and revascularization in order to induce osteoblasts migration, 
leading to osteogenesis [244]. In the present study, the combined effects of 
PRGF and bone xenograft in treating experimental critical size bony defects 
created in rabbit tibia were evaluated. Histological evaluation revealed that Bio-
Oss is a biocompatible, osteoconductive grafting material with no sign of foreign 
body reaction and/or severe inflammation after its application. The addition of 
PRGF to this bone substitute did not affect its biocompatibility, as also reported 
in previous studies [245-248]. Regarding the amount of newly regenerated bone 
and remaining biomaterial particles, taken together the data from the 
histomorphometric analysis showed that the addition of PRGF to the biomaterial 
caused an increase in bone formation at 8 weeks, in comparison to Bio-Oss 
alone and control groups, although it was not statistically significant. These 
findings are in accordance with other studies [248-250] and this could be related 
to the properties of PRGF that favors the increase of bone metabolism and 
consequently might accelerate the rate of degradation of the biomaterial [248]. 
Nonetheless, in the present study, we found similar results when comparing 
Bio-Oss and sham, as the biomaterial alone could not significantly increase 
bone formation respect to the control group. These results could be probably 
attributed to an inadequate sample size, to the defect size (bigger defects could 
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not be created due to the small tibia dimensions) and to the time period of just 8 
weeks that, given the fast metabolism of rabbits, might be sufficient to achieve 
complete bone healing also in the control sites. On the other hand, replacement 
of bovine bone mineral with natural bone appeared to be a slow process [245] 
then, since Bio-Oss is a hydroxyapatite compound, it is expected to have a 
slower rate of absorption. Therefore, also later findings could be important. 
Conversely, the addition of PRGF increased the rate of degradation of the 
biomaterial at 8 weeks. As Marx stated, platelet concentrates work via 
degranulation of platelets α granules that contain growth factors which, after 
being secreted, bind to the external surface of cell membranes of cells in the 
graft, flap or wound. Mesenchymal stem cells and osteoblasts are the principal 
type of cells expressing these trans-membrane receptors. Therefore, the 
addition of platelet concentrates to several grafting materials accelerates 
recruitment of osteoblasts and most probably, mesenchymal stem cells to the 
grafted area. This stimulates cellular proliferation, matrix formation, and osteoid 
and collagen production [217]. Accordingly, it can be postulated that platelet 
concentrates, such as PRGF, accelerate the remodeling process in which 
osteoclasts arrive at the grafted area more quickly and invade bone substitute’s 
particles more effectively [217]. Additionally, differences in the study design 
(animal/human), collection efficiency of the platelet concentrates kit, evaluation 
methods (radiography/histology) and defects shape, size and configuration, 
may be implicated for the discrepancy in the results of platelet concentrate 
studies [247]. 
To date, also the amount of basic research about the effect of PCs on in vitro 
cultures is limited [251] and conflicting [232]. The current study indicated that 
PRGF technology favored proliferation of both osteoblasts and fibroblasts, in 
accordance with previous investigations on platelet concentrates [94, 95, 228, 
231, 252]. Nevertheless, a number of studies evaluating the in vitro influence of 
PCs failed to demonstrate positive effects [100, 231]. 
In the current study, PRGF was prepared and utilized adopting the same 
protocol as in clinical application, except for the freeze-thawing cycle prior to the 
cell application. The latter, in fact, was demonstrated to have no consequences 
on PC biological activity [253]. The possibility to store platelet concentrates and 
the effects of freeze-thawing cycles on platelet activity are poorly understood 
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and still under debate. Some researchers consider freeze-thawing a procedure 
that could impair platelet function and lifespan, alter the GFs’ release pattern, 
promote the pyrogenic cytokines accumulation and increase the risk of bacterial 
proliferation [254], while other authors believe that it does not affect the platelet 
concentrate’s final properties [112]. Despite Zimmermann et al. [255] reported 
that freezing and thawing damaged platelet membranes, causing extensive 
degranulation and increase of GFs content in plasma, Perut et al. [256] showed 
that this procedure reduced platelet number, but did not affect the GFs release. 
This result was also confirmed by Roffi et al. [253] whose study underlined that 
although freezing and thawing affected the GFs release kinetics, fresh and 
frozen PCs did not significantly differ in their ability to induce cell proliferation. 
This storage option could simplify the management of patients undergoing 
multiple PC application sessions, keeping however in mind that biological 
results cannot always be directly translated into clinical outcomes [253]. Another 
interesting issue is the possibility that a prolonged storage time could have a 
strong influence on the results of platelet concentrates interactions with cells. 
Currently, there is a lack of data available about the preservation of biological 
activity potency of PCs after different storage times, but Anitua et al. [257] 
demonstrated that PRGF eye drops stored at -20°C fo r 15, 30 and 90 days 
maintained the same concentrations of the main proteins and growth factors, 
and did not affect the in vitro effects of the eye drops, therefore this point will be 
of great interest for future investigations. 
Despite platelet count and PC growth factors content are likely influenced by the 
donor’s age, gender and thrombocyte count, Weibrich et al. [258] did not find 
substantial variation in individual growth factors content and the donor’s 
biological condition. In fact, our results indicated an improvement of the 
biological analyzed parameters despite a mild inter-donor variability of the 
tested PCs. 
Aside from proliferation, the study herein presented also examined the PRGF 
pro-osteogenic activity by alkaline phosphatase activity (ALP) determination, an 
early osteogenic differentiation marker. Cells were maintained in media 
supplemented with 2.5% platelet concentrate, indicating that even such low 
amount of PC was adequate to induce cell survival. ALP activity assay showed 
that 2.5% PRGF is capable to support in vitro differentiation of hASCs 
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suggesting that platelet concentrates contain per se osteo-inductive factors 
which might activate some early steps of the osteo-differentiative process of 
mesenchymal cells. Our results are consistent with previous findings that 
demonstrated that the adjunct of platelet concentrates to culture medium 
promotes the differentiation of various cell types [95, 256]. Regarding the hOb 
function in terms of osteoblastic differentiation, our results cannot confirm a 
substantial contribution of PC to hOb differentiation. Interestingly, different 
papers indicated stimulation of the osteogenic differentiation potential of PCs 
[226, 259, 260], while others reported their inhibitory effect [231, 261, 262]. 
Such contradictory results could be explained by the great variability among 
PCs preparation methods and consequently their different cell content and 
growth factors concentration [232]. A higher platelet concentration should be in 
theory associated with an elevated growth factors content and consequently 
with an expected major effect on tissue regeneration [228]. Conversely, recent 
studies showed that cell proliferation is induced by platelet concentrates in a 
non-concentration-dependent manner. Indeed, higher platelet concentrations 
may have an inhibitory effect and may decrease the proliferation process in vitro 
[96, 231, 263]. This non direct-correlation between platelet count and growth 
factors concentration and the unclear relationship between platelet count and 
cellular response, was also reported by Zimmermann et al. [264] and Eppley et 
al. [220]. On the other hand, other authors reported that platelet count positively 
correlates with the quantity of growth factors released [265]. In principle, several 
factors should be considered that may affect the establishment of precise 
correlations. For example, the content of GFs stored in, and the amount of GFs 
released by each cell may vary. We should keep in mind that platelets derive 
from fragmentation of larger cells, the megakaryocites, and this process does 
not always generate identical cells. Furthermore, platelets activation, which 
causes discharge of platelets granules content by exocytosis in the extracellular 
space, may not occur in the same way and simultaneously for all the platelets 
involved, especially in the in vivo situation. The GFs release kinetics may vary 
according to the interaction of platelets with the surrounding extracellular matrix 
and/or with other cells and biological mediators involved in early healing events 
[112]. Another possible explanation is that after platelet activation, not only a 
variety of GFs but also other proteins such as fibrinogen, β-glucuronidase, 
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thrombospondin and further coagulation factors, are released [233], that might 
interfere with the healing process. In particular, thrombospondin-1 (TSP-1) is an 
important angiogenesis inhibitor that is present in significant quantity in PCs. 
Cell proliferation reduction could be due to the elevated TSP-1 secretion in 
concentrated PC that possibly contribute to the antiproliferative effect via cell 
apoptosis [233]. In addition, Liu et al. [266] suggested that the cell proliferation 
was influenced by the pH as high PC concentrations resulted in pH increase 
that negatively affected the proliferation process. In particular, the precise PC 
concentration that would be optimal in promoting wound healing and 
regeneration is still undetermined. Therefore, more studies are necessary to 
establish if and how progressively higher PCs concentrations would influence 
the cell proliferation. A further limitation is that, according to the Anitua’s 
protocol for PRGF production, leukocytes are intentionally excluded in order to 
avoid pro-inflammatory effects of proteases and acid hydrolases contained in 
white blood cells [267]. On the other hand, such manual procedure to excluding 
leukocytes may yield poorly reproducible results. After a low spin centrifugation, 
most platelets and leukocytes lie in the intermediate buffy coat, leading to a low 
platelet collection efficiency. Furthermore, the several manipulating steps, 
needed both to discharge the acellular plasma and to collect the entire PRGF 
fraction, might be associated with possible handling errors. The PRGF clot 
formed after activation is unstable and need to be applied immediately [134]. 
The lack of consistency and standardization in the PCs preparation may 
influence the research findings and the comparison among different studies 
[268]. 
Considering all the information from the literature, the results herein presented 
indicated that PRGF enhanced simultaneously both cell proliferative and 
differentiative capacity in vitro of all the investigated cell types, suggesting also 
that the concentrated cocktail of bioactive components present in platelet rich 
preparations could be a valid alternative to FBS as supplement for culture 
medium as also suggested by Lucarelli et al. [269] and Creeper et al. [95]. 
Additionally, since osteoblasts growth was lower than adipose-derived stem 
cells and fibroblasts, it can be postulated that this difference in proliferation rate 
could be due to the difficulty of maintaining hObs in culture and to the lower PC 
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concentration used to supplement the cell culture medium compared to other 
studies [94, 96]. 
An in vitro model for the investigation of the PC effects on cell proliferation and 
differentiation of primary cells was adopted in this study, hoping to determine 
possible correlations with the wound healing scenario in vivo, taking however 
into account that in vitro results could only be partially compared to the in vivo 
condition. In fact, the biological environment of a healing tissue is extremely 
more complex and undergoes continuous modifications regarding cell 
composition, tissue pH, oxygen level and soluble mediators content. In fact, in 
vivo, a far greater number of signaling molecules are involved and may interact 
with platelets and other cells in orchestrating the healing process. Recent 
proteomics studies showed that more than 4000 soluble factors are contained 
into and released by the platelet granules, and for most of them the actual role 
is still unknown [270]. Additional studies focusing on the proteomic analysis of 
the plasma concentrates with the idea to deplete some factors involved in the 
healing process, are needed to shed light on the actual role of platelets in the 
tissue regeneration process. Since large heterogeneity in clinical outcomes has 
been evidenced by many systematic reviews [271], more standardized clinical 
studies should be designed. 
It can be concluded that PRGF supports the stimulation of wound healing and 
tissue regeneration in terms of cell proliferation and viability both in vitro and in 
vivo. Consequently, we provide evidence to support the clinical application of 
activated platelet concentrates in healing therapies. 
References 
 
70 
 
References 
 
1. Italiano, J.E., Jr., et al., Blood platelets are assembled principally at the 
ends of proplatelet processes produced by differentiated megakaryocytes. 
J Cell Biol, 1999. 147(6): p. 1299-312. 
2. Welsh, W.J., Autologous platelet gel: Clinical function and usage in plastic 
surgery. Cosmetic Derm, 2000. 11: p. 13. 
3. Ogawa, D., Differentiation and proliferation of hematopoietic stem cells. 
Blood 1993. 81: p. 2844-2853. 
4. Long, M.W., N. Williams, and S. Ebbe, Immature megakaryocytes in the 
mouse: physical characteristics, cell cycle status, and in vitro 
responsiveness to thrombopoietic stimulatory factor. Blood, 1982. 59(3): p. 
569-75. 
5. Briddell, R.A., et al., Characterization of the human burst-forming unit-
megakaryocyte. Blood, 1989. 74(1): p. 145-51. 
6. Kaushansky, K., The molecular mechanisms that control thrombopoiesis. 
J Clin Invest, 2005. 115(12): p. 3339-47. 
7. Kaushansky, K. and J.G. Drachman, The molecular and cellular biology of 
thrombopoietin: the primary regulator of platelet production. Oncogene, 
2002. 21(21): p. 3359-67. 
8. Ebbe, S., Biology of megakaryocytes. Prog Hemost Thromb, 1976. 3: p. 
211-29. 
9. Yamada, F., The fine structure of the megakaryocyte in the mouse spleen. 
Acta Anat. (Basel), 1957. 29: p. 267-290. 
10. Behnke, O., An electron microscope study of the megacaryocyte of the rat 
bone marrow. I. The development of the demarcation membrane system 
and the platelet surface coat. J Ultrastruct Res, 1968. 24(5): p. 412-33. 
11. Nakao, K. and A.A. Angrist, Membrane surface specialization of blood 
platelet and megakaryocyte. Nature, 1968. 217(5132): p. 960-1. 
12. Kosaki, G., K. Inosita, and H. Okuma, Human thrombocytogenesis. In: 
Didisheim P, ed. Platelets, Thrombosis, and Inhibitors. Vol 97. Stuttgart-
New York: FK Shattauer. 1974: p. 97-102. 
References 
 
71 
 
13. Djaldetti, M., et al., SEM observations on the mechanism of platelet 
release from megakaryocytes. Thromb Haemost, 1979. 42(2): p. 611-20. 
14. Becker, R.P. and P.P. De Bruyn, The transmural passage of blood cells 
into myeloid sinusoids and the entry of platelets into the sinusoidal 
circulation; a scanning electron microscopic investigation. Am J Anat, 
1976. 145(2): p. 183-205. 
15. White, J.G. and G. Escolar, Current concepts of platelet membrane 
response to surface activation. Platelets, 1993. 4(4): p. 175-89. 
16. White, J.G., Platelet morphology. In S. E. Johnson (Ed.), The circulating 
platelet. New York: Academic Press. 1971: p. 45–121. 
17. Clemetson, K.J., Glycoproteins of the platelet plasma membrane. In J. N. 
George, A. T. Nurden, & D. R. Phillips (Eds.), Platelet membrane 
glycoproteins. New York: Plenum Press. 1985: p. 145–169. 
18. Phillips, D.R., Receptors for platelet agonists. In J. N. George, A. T. 
Nurden, & D. R. Phillips (Eds.), Platelet membrane glycoproteins. New 
York: Plenum Press. 1985: p. 51–85. 
19. Kunicki, T.J., Platelet glycoprotein antigens and immune receptors. Prog 
Clin Biol Res, 1988. 283: p. 87-123. 
20. Behnke, O., The morphology of blood platelet membrane systems. Ser 
Haematol, 1970. 3(4): p. 3-16. 
21. White, J.G., The submembrane filaments of blood platelets. Am J Pathol, 
1969. 56(2): p. 267-77. 
22. Heijnen, H.F., et al., Multivesicular bodies are an intermediate stage in the 
formation of platelet alpha-granules. Blood, 1998. 91(7): p. 2313-25. 
23. McFadyen, J.D. and Z.S. Kaplan, Platelets are not just for clots. Transfus 
Med Rev, 2015. 29(2): p. 110-9. 
24. Frojmovic, M.M. and J.G. Milton, Human platelet size, shape, and related 
functions in health and disease. Physiol Rev, 1982. 62(1): p. 185-261. 
25. Harrison, P. and E.M. Cramer, Platelet alpha-granules. Blood Rev, 1993. 
7(1): p. 52-62. 
26. Berger, G., J.M. Masse, and E.M. Cramer, Alpha-granule membrane 
mirrors the platelet plasma membrane and contains the glycoproteins Ib, 
IX, and V. Blood, 1996. 87(4): p. 1385-95. 
References 
 
72 
 
27. Israels, S.J., et al., The lysosomal granule membrane protein, LAMP-2, is 
also present in platelet dense granule membranes. Thromb Haemost, 
1996. 75(4): p. 623-9. 
28. Ehrlich, H.P. and J.L. Gordon, Proteinases in platelets (Vol. 1). New York: 
Elsevier. 1976. 
29. Dangelmaier, C.A. and H. Holmsen, Determination of acid hydrolases in 
human platelets. Anal Biochem, 1980. 104(1): p. 182-91. 
30. Coppinger, J.A., et al., Characterization of the proteins released from 
activated platelets leads to localization of novel platelet proteins in human 
atherosclerotic lesions. Blood, 2004. 103(6): p. 2096-104. 
31. Macaulay, I.C., et al., Platelet genomics and proteomics in human health 
and disease. J Clin Invest, 2005. 115(12): p. 3370-7. 
32. Gibbins, J.M., et al., Glycoprotein VI is the collagen receptor in platelets 
which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. 
FEBS Lett, 1997. 413(2): p. 255-9. 
33. Barnes, M.J., C.G. Knight, and R.W. Farndale, The collagen-platelet 
interaction. Curr Opin Hematol, 1998. 5(5): p. 314-20. 
34. Hawiger, J., Adhesive interactions of blood cells and the vascular wall in 
hemostasis and thrombosis. In: R. W. Colman, J. Hirsh, V. J. Marder, A. 
W. Clowes, & J. N. George (Eds.), Hemostasis and thrombosis: Basic 
principles & clinical practice. Philadelphia: Lippincott Williams & Wilkins. 
2001: p. 639–660. 
35. Conley, C.L., Hemostasis. In: V. B. Mountcastle (Ed.), Medical Physiology. 
St. Louis: Mosby. 2004: p. 1137-1146. 
36. Caro, C.D., et al., The Mechanics of the Circulation. Oxford: Oxford 
University Press, 1978. 
37. Majerus, P.W., in: The Molecular Basis of Blood Diseases 
(Stamatoyannopoulos, G., Nienhuis, A. W., Leder, P., & Majerus, P. W., 
Eds.), W. B. Saunders Co., Philadelphia, PA. 1987: p. 689-721. 
38. Guyton, A.C., Physiology of the Human Body. Philadelphia: Saunders 
College Publishing, 1979. 
39. Bhanot, S. and J.C. Alex, Current applications of platelet gels in facial 
plastic surgery. Facial Plast Surg, 2002. 18(1): p. 27-33. 
References 
 
73 
 
40. Szpaderska, A.M., et al., The effect of thrombocytopenia on dermal wound 
healing. J Invest Dermatol, 2003. 120(6): p. 1130-7. 
41. Anderson, J.M., The cellular cascades of wound healing. In: J. E. Davies 
(Ed.), Bone Engineering. Toronto: em squared inc. 2000: p. 81-93. 
42. Clark, R.A.F., Wound repair. Overview and general considerations. In: 
Clark RAF, editor. The Molecular and Cellular Biology of Wound Repair, 
2nd edn. New York, NY: Plenum Press. 1996: p. 3-50. 
43. Buckwalter, J.A., et al., Healing of musculoskeletal tissues. In C. A. 
Rockwood, Jr., R. W. Bucholz, and D. P. Green (Eds.), Fractures in 
Adults. Philadelphia: Lippincott-Raven. 1996: p. 261-304. 
44. Martin, P., Wound healing--aiming for perfect skin regeneration. Science, 
1997. 276(5309): p. 75-81. 
45. Aukhil, I., Biology of wound healing. Periodontol 2000, 2000. 22: p. 44-50. 
46. Werner, S. and R. Grose, Regulation of wound healing by growth factors 
and cytokines. Physiol Rev, 2003. 83(3): p. 835-70. 
47. Williams, D.F., To engineer is to create: the link between engineering and 
regeneration. Trends Biotechnol, 2006. 24(1): p. 4-8. 
48. Chen, F.M., et al., Localized delivery of growth factors for periodontal 
tissue regeneration: role, strategies, and perspectives. Med Res Rev, 
2009. 29(3): p. 472-513. 
49. Babensee, J.E., L.V. McIntire, and A.G. Mikos, Growth factor delivery for 
tissue engineering. Pharm Res, 2000. 17(5): p. 497-504. 
50. McKay, I.A. and I. Leigh, Growth Factors: A Practical Approach IRL Press, 
Oxford. 1993. 
51. Bowen-Pope, D.F., et al., Platelet-derived growth factor in vivo: levels, 
activity, and rate of clearance. Blood, 1984. 64(2): p. 458-69. 
52. Edmonds, M., et al., New treatments in ulcer healing and wound infection. 
Diabetes Metab Res Rev, 2000. 16 Suppl 1: p. S51-4. 
53. Harding, K.G., H.L. Morris, and G.K. Patel, Science, medicine and the 
future: healing chronic wounds. BMJ, 2002. 324(7330): p. 160-3. 
54. Heldin, C.H., U. Eriksson, and A. Ostman, New members of the platelet-
derived growth factor family of mitogens. Arch Biochem Biophys, 2002. 
398(2): p. 284-90. 
References 
 
74 
 
55. Heldin, C.H. and B. Westermark, Mechanism of action and in vivo role of 
platelet-derived growth factor. Physiol Rev, 1999. 79(4): p. 1283-316. 
56. Nagai, M.K. and J.M. Embil, Becaplermin: recombinant platelet derived 
growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin 
Biol Ther, 2002. 2(2): p. 211-8. 
57. Ross, R., et al., A platelet-dependent serum factor that stimulates the 
proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S 
A, 1974. 71(4): p. 1207-10. 
58. Vogt, P.M., et al., Determination of endogenous growth factors in human 
wound fluid: temporal presence and profiles of secretion. Plast Reconstr 
Surg, 1998. 102(1): p. 117-23. 
59. Niessen, F.B., et al., Keratinocyte-derived growth factors play a role in the 
formation of hypertrophic scars. J Pathol, 2001. 194(2): p. 207-16. 
60. Haisa, M., H. Okochi, and G.R. Grotendorst, Elevated levels of PDGF 
alpha receptors in keloid fibroblasts contribute to an enhanced response to 
PDGF. J Invest Dermatol, 1994. 103(4): p. 560-3. 
61. Ornitz, D.M. and N. Itoh, Fibroblast growth factors. Genome Biol, 2001. 
2(3): p. REVIEWS3005. 
62. Johnson, D.E. and L.T. Williams, Structural and functional diversity in the 
FGF receptor multigene family. Adv Cancer Res, 1993. 60: p. 1-41. 
63. Ornitz, D.M., et al., Receptor specificity of the fibroblast growth factor 
family. J Biol Chem, 1996. 271(25): p. 15292-7. 
64. Ornitz, D.M., FGFs, heparan sulfate and FGFRs: complex interactions 
essential for development. Bioessays, 2000. 22(2): p. 108-12. 
65. Werner, S., Keratinocyte growth factor: a unique player in epithelial repair 
processes. Cytokine Growth Factor Rev, 1998. 9(2): p. 153-65. 
66. Abraham, J.A. and M. Klagsbrun, Modulation of wound repair by members 
of the fibroblast growth factor family. In: The Molecular and Cellular 
Biology of Wound Repair (2nd ed.), edited by Clark RAF. New York: 
Plenum. 1996: p. 195-248. 
67. Risau, W., Angiogenic growth factors. Prog Growth Factor Res, 1990. 
2(1): p. 71-9. 
68. Tsahar, E., et al., Pathogenic poxviruses reveal viral strategies to exploit 
the ErbB signaling network. EMBO J, 1998. 15: p. 5948-5963. 
References 
 
75 
 
69. Strachan, L., et al., Cloning and biological activity of epigen, a novel 
member of the epidermal growth factor superfamily. J Biol Chem, 2001. 
276(21): p. 18265-71. 
70. Yarden, Y., The EGFR family and its ligands in human cancer. signalling 
mechanisms and therapeutic opportunities. Eur J Cancer, 2001. 37 Suppl 
4: p. S3-8. 
71. Greenhalgh, D.G., The role of growth factors in wound healing. J Trauma, 
1996. 41(1): p. 159-67. 
72. Gale, N.W. and G.D. Yancopoulos, Growth factors acting via endothelial 
cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins 
in vascular development. Genes Dev, 1999. 13(9): p. 1055-66. 
73. O'Dell, S.D. and I.N. Day, Insulin-like growth factor II (IGF-II). Int J 
Biochem Cell Biol, 1998. 30(7): p. 767-71. 
74. Clemmons, D.R., Insulin-like growth factor binding proteins and their role 
in controlling IGF actions. Cytokine Growth Factor Rev, 1997. 8(1): p. 45-
62. 
75. Lynch, S.E., R.B. Colvin, and H.N. Antoniades, Growth factors in wound 
healing. Single and synergistic effects on partial thickness porcine skin 
wounds. J Clin Invest, 1989. 84(2): p. 640-6. 
76. Lewin, G.R. and L.M. Mendell, Nerve growth factor and nociception. 
Trends Neurosci, 1993. 16(9): p. 353-9. 
77. Li, A.K., et al., Nerve growth factor: acceleration of the rate of wound 
healing in mice. Proc Natl Acad Sci U S A, 1980. 77(7): p. 4379-81. 
78. Matsuda, H., et al., Role of nerve growth factor in cutaneous wound 
healing: accelerating effects in normal and healing-impaired diabetic mice. 
J Exp Med, 1998. 187(3): p. 297-306. 
79. Bernabei, R., et al., Effect of topical application of nerve-growth factor on 
pressure ulcers. Lancet, 1999. 354(9175): p. 307. 
80. Massague, J., The transforming growth factor-beta family. Annu Rev Cell 
Biol, 1990. 6: p. 597-641. 
81. Wakefield, L.M. and A.B. Roberts, TGF-beta signaling: positive and 
negative effects on tumorigenesis. Curr Opin Genet Dev, 2002. 12(1): p. 
22-9. 
References 
 
76 
 
82. Roberts, A.B., Molecular and cell biology of TGF-beta. Miner Electrolyte 
Metab, 1998. 24(2-3): p. 111-9. 
83. Massague, J., TGF-beta signal transduction. Annu Rev Biochem, 1998. 
67: p. 753-91. 
84. Blair, P. and R. Flaumenhaft, Platelet alpha-granules: basic biology and 
clinical correlates. Blood Rev, 2009. 23(4): p. 177-89. 
85. Gurtner, G.C., et al., Wound repair and regeneration. Nature, 2008. 
453(7193): p. 314-21. 
86. Street, J., et al., Vascular endothelial growth factor stimulates bone repair 
by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A, 
2002. 99(15): p. 9656-61. 
87. Anitua, E., et al., Delivering growth factors for therapeutics. Trends 
Pharmacol Sci, 2008. 29(1): p. 37-41. 
88. Ruiz, C., et al., Expression of cytokines IL-4, IL-12, IL-15, IL-18, and 
IFNgamma and modulation by different growth factors in cultured human 
osteoblast-like cells. J Bone Miner Metab, 2007. 25(5): p. 286-92. 
89. Reyes-Botella, C., et al., Antigenic phenotype of cultured human 
osteoblast-like cells. Cell Physiol Biochem, 2002. 12(5-6): p. 359-64. 
90. Garcia-Martinez, O., et al., Effect of platelet-rich plasma on growth and 
antigenic profile of human osteoblasts and its clinical impact. J Oral 
Maxillofac Surg, 2012. 70(7): p. 1558-64. 
91. Marden, L.J., et al., Platelet-derived growth factor inhibits bone 
regeneration induced by osteogenin, a bone morphogenetic protein, in rat 
craniotomy defects. J Clin Invest, 1993. 92(6): p. 2897-905. 
92. Jingushi, S., et al., Acidic fibroblast growth factor (aFGF) injection 
stimulates cartilage enlargement and inhibits cartilage gene expression in 
rat fracture healing. J Orthop Res, 1990. 8(3): p. 364-71. 
93. Bolander, M.E., Regulation of fracture repair by growth factors. Proc Soc 
Exp Biol Med, 1992. 200(2): p. 165-70. 
94. Ferreira, C.F., et al., Platelet-rich plasma influence on human osteoblasts 
growth. Clin Oral Implants Res, 2005. 16(4): p. 456-60. 
95. Creeper, F., et al., The effect of platelet-rich plasma on osteoblast and 
periodontal ligament cell migration, proliferation and differentiation. J 
Periodontal Res, 2009. 44(2): p. 258-65. 
References 
 
77 
 
96. Anitua, E., et al., Plasma rich in growth factors promotes bone tissue 
regeneration by stimulating proliferation, migration, and autocrine 
secretion in primary human osteoblasts. J Periodontol, 2013. 84(8): p. 
1180-90. 
97. Choi, B.H., et al., Effect of platelet-rich plasma on bone regeneration in 
autogenous bone graft. Int J Oral Maxillofac Surg, 2004. 33(1): p. 56-9. 
98. Weibrich, G., et al., Effect of platelet concentration in platelet-rich plasma 
on peri-implant bone regeneration. Bone, 2004. 34(4): p. 665-71. 
99. Taschieri, S., et al., Treatment of through-and-through bone lesion using 
autologous growth factors and xenogeneic bone graft: a case report. Oral 
Maxillofac Surg, 2012. 16(1): p. 57-64. 
100. Slapnicka, J., et al., Effects of activated and nonactivated platelet-rich 
plasma on proliferation of human osteoblasts in vitro. J Oral Maxillofac 
Surg, 2008. 66(2): p. 297-301. 
101. Hom, D.B. and R.H. Maisel, Angiogenic growth factors: their effects and 
potential in soft tissue wound healing. Ann Otol Rhinol Laryngol, 1992. 
101(4): p. 349-54. 
102. Brown, G.L., et al., Enhancement of wound healing by topical treatment 
with epidermal growth factor. N Engl J Med, 1989. 321(2): p. 76-9. 
103. Robson, M.C., et al., The safety and effect of topically applied recombinant 
basic fibroblast growth factor on the healing of chronic pressure sores. 
Ann Surg, 1992. 216(4): p. 401-6; discussion 406-8. 
104. Mustoe, T.A., et al., A phase II study to evaluate recombinant platelet-
derived growth factor-BB in the treatment of stage 3 and 4 pressure 
ulcers. Arch Surg, 1994. 129(2): p. 213-9. 
105. Steed, D.L., Clinical evaluation of recombinant human platelet-derived 
growth factor for the treatment of lower extremity diabetic ulcers. Diabetic 
Ulcer Study Group. J Vasc Surg, 1995. 21(1): p. 71-8; discussion 79-81. 
106. Krupski, W.C., et al., A prospective randomized trial of autologous platelet-
derived wound healing factors for treatment of chronic nonhealing wounds: 
a preliminary report. J Vasc Surg, 1991. 14(4): p. 526-32; discussion 532-
6. 
References 
 
78 
 
107. Cohen, I.K., et al., Topical application of epidermal growth factor onto 
partial-thickness wounds in human volunteers does not enhance 
reepithelialization. Plast Reconstr Surg, 1995. 96(2): p. 251-4. 
108. Robson, M.C., T.A. Mustoe, and T.K. Hunt, The future of recombinant 
growth factors in wound healing. Am J Surg, 1998. 176(2A Suppl): p. 80S-
82S. 
109. Knighton, D.R., et al., Classification and treatment of chronic nonhealing 
wounds. Successful treatment with autologous platelet-derived wound 
healing factors (PDWHF). Ann Surg, 1986. 204(3): p. 322-30. 
110. Dohan, D.M., et al., Platelet-rich fibrin (PRF): a second-generation platelet 
concentrate. Part I: technological concepts and evolution. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endod, 2006. 101(3): p. e37-44. 
111. Dohan Ehrenfest, D.M., et al., In search of a consensus terminology in the 
field of platelet concentrates for surgical use: platelet-rich plasma (PRP), 
platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr 
Pharm Biotechnol, 2012. 13(7): p. 1131-7. 
112. Anitua, E., et al., Autologous platelets as a source of proteins for healing 
and tissue regeneration. Thromb Haemost, 2004. 91(1): p. 4-15. 
113. Spotnitz, W.D. and S. Burks, Hemostats, sealants, and adhesives: 
components of the surgical toolbox. Transfusion, 2008. 48(7): p. 1502-16. 
114. Bergel, S., Uber wirkungen des fibrins. Dtsch Med Wochenschr 1909. 35: 
p. 633. 
115. Grey, E.G., Fibrin as a hemostatic in cerebral surgery. Surg gynecol 
obstet, 1915. 21: p. 452-454. 
116. Young, J.Z. and P.B. Medar, Fibrin suture of peripheral nerves. Lancet, 
1940. 275: p. 126-132. 
117. Tidrick, R.T. and E.D. Warner, Fibrin fixation of skin transplants. Surgery, 
1944. 15: p. 90-95. 
118. Matras, H., et al., [Suture-free interfascicular nerve transplantation in 
animal experiments]. Wien Med Wochenschr, 1972. 122(37): p. 517-23. 
119. Dresdale, A., et al., Preparation of fibrin glue from single-donor fresh-
frozen plasma. Surgery, 1985. 97(6): p. 750-5. 
120. Martinowitz, U. and R. Saltz, Fibrin sealant. Curr Opin Hematol, 1996. 
3(5): p. 395-402. 
References 
 
79 
 
121. Dunn, C.J. and K.L. Goa, Fibrin sealant: a review of its use in surgery and 
endoscopy. Drugs, 1999. 58(5): p. 863-86. 
122. Brennan, M., Fibrin glue. Blood Rev, 1991. 5(4): p. 240-4. 
123. Silver, F.H., M.C. Wang, and G.D. Pins, Preparation and use of fibrin glue 
in surgery. Biomaterials, 1995. 16(12): p. 891-903. 
124. Sierra, D.H., Fibrin sealant adhesive systems: a review of their chemistry, 
material properties and clinical applications. J Biomater Appl, 1993. 7(4): 
p. 309-52. 
125. Redl, H., G. Schlag, and H.P. Dinges, Methods of fibrin seal application. 
Thorac Cardiovasc Surg, 1982. 30(4): p. 223-7. 
126. Radosevich, M., H.I. Goubran, and T. Burnouf, Fibrin sealant: scientific 
rationale, production methods, properties, and current clinical use. Vox 
Sang, 1997. 72(3): p. 133-43. 
127. Hunt, T.K. and W. Van Winkle, Jr., Fundamentals of wound management 
in surgery. In: Wound Healing: Disorders of Repair. South Plainfield, NJ: 
Chirugicom. 1976. 
128. Whitman, D.H., R.L. Berry, and D.M. Green, Platelet gel: an autologous 
alternative to fibrin glue with applications in oral and maxillofacial surgery. 
J Oral Maxillofac Surg, 1997. 55(11): p. 1294-9. 
129. Valbonesi, M., Fibrin glues of human origin. Best Pract Res Clin Haematol, 
2006. 19(1): p. 191-203. 
130. Hood, A.G., A.G. Hill, and G.D. Reeder, Perioperative Autologous 
Sequestration III: A New Physiologic Glue with Wound Healing Properties. 
Proceedings of the American Academy of Cardiovascular Perfusion. 1993. 
14: p. 126. 
131. Kingsley, C.S., Blood coagulation; evidence of an antagonist to factor VI in 
platelet-rich human plasma. Nature, 1954. 173(4407): p. 723-4. 
132. Marx, R.E., et al., Platelet-rich plasma: Growth factor enhancement for 
bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998. 
85(6): p. 638-46. 
133. Marx, R.E., Platelet-rich plasma (PRP): what is PRP and what is not PRP? 
Implant Dent, 2001. 10(4): p. 225-8. 
134. Dohan Ehrenfest, D.M., L. Rasmusson, and T. Albrektsson, Classification 
of platelet concentrates: from pure platelet-rich plasma (P-PRP) to 
References 
 
80 
 
leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol, 2009. 27(3): 
p. 158-67. 
135. Anitua, E., Plasma rich in growth factors: preliminary results of use in the 
preparation of future sites for implants. Int J Oral Maxillofac Implants, 
1999. 14(4): p. 529-35. 
136. Weibrich, G., et al., Comparison of the platelet concentrate collection 
system with the plasma-rich-in-growth-factors kit to produce platelet-rich 
plasma: a technical report. Int J Oral Maxillofac Implants, 2005. 20(1): p. 
118-23. 
137. Choukroun, J., et al., Une opportunité en paro-implantologie : le PRF. 
Implantodontie, 2001. 42: p. 55-62. 
138. Dohan, D.M., et al., Platelet-rich fibrin (PRF): a second-generation platelet 
concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod, 2006. 101(3): p. e45-50. 
139. Dohan, D.M., et al., Platelet-rich fibrin (PRF): a second-generation platelet 
concentrate. Part III: leucocyte activation: a new feature for platelet 
concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006. 
101(3): p. e51-5. 
140. DeLong, J.M., R.P. Russell, and A.D. Mazzocca, Platelet-rich plasma: the 
PAW classification system. Arthroscopy, 2012. 28(7): p. 998-1009. 
141. Tayapongsak, P., et al., Autologous fibrin adhesive in mandibular 
reconstruction with particulate cancellous bone and marrow. J Oral 
Maxillofac Surg, 1994. 52(2): p. 161-5; discussion 166. 
142. Georgakopoulos, I., et al., The impact of Platelet Rich Plasma (PRP) in 
osseointegration of oral implants in dental panoramic radiography: texture 
based evaluation. Clin Cases Miner Bone Metab, 2014. 11(1): p. 59-66. 
143. Taschieri, S., et al., Platelet-Rich Plasma and Deproteinized Bovine Bone 
Matrix in Maxillary Sinus Lift Surgery: A Split-Mouth Histomorphometric 
Evaluation. Implant Dent, 2015. 24(5): p. 592-7. 
144. Barber, F.A., et al., Rotator cuff repair healing influenced by platelet-rich 
plasma construct augmentation. Arthroscopy, 2011. 27(8): p. 1029-35. 
145. Finnoff, J.T., et al., Treatment of chronic tendinopathy with ultrasound-
guided needle tenotomy and platelet-rich plasma injection. PM R, 2011. 
3(10): p. 900-11. 
References 
 
81 
 
146. Frykberg, R.G., et al., Chronic wounds treated with a physiologically 
relevant concentration of platelet-rich plasma gel: a prospective case 
series. Ostomy Wound Manage, 2010. 56(6): p. 36-44. 
147. Greppi, N., et al., Treatment of recalcitrant ulcers with allogeneic platelet 
gel from pooled platelets in aged hypomobile patients. Biologicals, 2011. 
39(2): p. 73-80. 
148. Saad Setta, H., et al., Platelet-rich plasma versus platelet-poor plasma in 
the management of chronic diabetic foot ulcers: a comparative study. Int 
Wound J, 2011. 8(3): p. 307-12. 
149. Senet, P., et al., Randomized trial and local biological effect of autologous 
platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc 
Surg, 2003. 38(6): p. 1342-8. 
150. Mazzucco, L., et al., The use of autologous platelet gel to treat difficult-to-
heal wounds: a pilot study. Transfusion, 2004. 44(7): p. 1013-8. 
151. Kazakos, K., et al., The use of autologous PRP gel as an aid in the 
management of acute trauma wounds. Injury, 2009. 40(8): p. 801-5. 
152. Man, D., H. Plosker, and J.E. Winland-Brown, The use of autologous 
platelet-rich plasma (platelet gel) and autologous platelet-poor plasma 
(fibrin glue) in cosmetic surgery. Plast Reconstr Surg, 2001. 107(1): p. 
229-37; discussion 238-9. 
153. Adler, S.C. and K.J. Kent, Enhancing wound healing with growth factors. 
Facial Plast Surg Clin North Am, 2002. 10(2): p. 129-46. 
154. Abuzeni, P. and R.W. Alexander, Enhancement of autologous fat 
transplantation with platelet rich plasma. Am J Cosmetic Surg 2001. 18: p. 
59. 
155. Schade, V.L. and T.S. Roukis, Use of platelet-rich plasma with split-
thickness skin grafts in the high-risk patient. Foot Ankle Spec, 2008. 1(3): 
p. 155-9. 
156. Lee, J.W., et al., The efficacy of autologous platelet rich plasma combined 
with ablative carbon dioxide fractional resurfacing for acne scars: a 
simultaneous split-face trial. Dermatol Surg, 2011. 37(7): p. 931-8. 
157. Cervelli, V., et al., Treatment of traumatic scars using fat grafts mixed with 
platelet-rich plasma, and resurfacing of skin with the 1540 nm nonablative 
laser. Clin Exp Dermatol, 2012. 37(1): p. 55-61. 
References 
 
82 
 
158. Prochazka, V., et al., Addition of platelet concentrate to dermo-epidermal 
skin graft in deep burn trauma reduces scarring and need for revision 
surgeries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 
2014. 158(2): p. 242-58. 
159. Pallua, N., T. Wolter, and M. Markowicz, Platelet-rich plasma in burns. 
Burns, 2010. 36(1): p. 4-8. 
160. Uebel, C.O., et al., The role of platelet plasma growth factors in male 
pattern baldness surgery. Plast Reconstr Surg, 2006. 118(6): p. 1458-66; 
discussion 1467. 
161. Takikawa, M., et al., Enhanced effect of platelet-rich plasma containing a 
new carrier on hair growth. Dermatol Surg, 2011. 37(12): p. 1721-9. 
162. Kamp, H., et al., Regulation of PDGF and PDGF receptor in cultured 
dermal papilla cells and follicular keratinocytes of the human hair follicle. 
Exp Dermatol, 2003. 12(5): p. 662-72. 
163. Cervelli, V., et al., Application of platelet-rich plasma in plastic surgery: 
clinical and in vitro evaluation. Tissue Eng Part C Methods, 2009. 15(4): p. 
625-34. 
164. Salgarello, M., G. Visconti, and A. Rusciani, Breast fat grafting with 
platelet-rich plasma: a comparative clinical study and current state of the 
art. Plast Reconstr Surg, 2011. 127(6): p. 2176-85. 
165. Alio, J.L., et al., Symptomatic dry eye treatment with autologous platelet-
rich plasma. Ophthalmic Res, 2007. 39(3): p. 124-9. 
166. Alio, J.L., et al., Use of autologous platelet-rich plasma in the treatment of 
dormant corneal ulcers. Ophthalmology, 2007. 114(7): p. 1286-1293 e1. 
167. Farrag, T.Y., et al., Effect of platelet rich plasma and fibrin sealant on 
facial nerve regeneration in a rat model. Laryngoscope, 2007. 117(1): p. 
157-65. 
168. Sariguney, Y., et al., Effect of platelet-rich plasma on peripheral nerve 
regeneration. J Reconstr Microsurg, 2008. 24(3): p. 159-67. 
169. Cho, H.H., et al., Effect of neural-induced mesenchymal stem cells and 
platelet-rich plasma on facial nerve regeneration in an acute nerve injury 
model. Laryngoscope, 2010. 120(5): p. 907-13. 
References 
 
83 
 
170. van der Hagen, S.J., et al., Autologous platelet derived grow factors 
(platelet rich plasma) as an adjunct to mucosal advancement flap in high 
cryptoglandular peri-anal fistulae: a pilot study. Colorectal Dis, 2009. 
171. Langer, R. and J.P. Vacanti, Tissue engineering. Science, 1993. 
260(5110): p. 920-6. 
172. Fuchs, J.R., B.A. Nasseri, and J.P. Vacanti, Tissue engineering: a 21st 
century solution to surgical reconstruction. Ann Thorac Surg, 2001. 72(2): 
p. 577-91. 
173. Langer, R.S. and J.P. Vacanti, Tissue engineering: the challenges ahead. 
Sci Am, 1999. 280(4): p. 86-9. 
174. Vacanti, J.P. and R. Langer, Tissue engineering: the design and 
fabrication of living replacement devices for surgical reconstruction and 
transplantation. Lancet, 1999. 354 Suppl 1: p. SI32-4. 
175. Bisceglie, V., Über die antineoplastische Immunität: heterologe 
Einpflanzung von Tumoren in Hühnerembryonen. Ztschr f Krebsforsch, 
1933. 40: p. 122-140. 
176. Chick, W.L., A.A. Like, and V. Lauris, Beta cell culture on synthetic 
capillaries: an artificial endocrine pancreas. Science, 1975. 187(4179): p. 
847-9. 
177. Burke, J.F., et al., Successful use of a physiologically acceptable artificial 
skin in the treatment of extensive burn injury. Ann Surg, 1981. 194(4): p. 
413-28. 
178. Bruder, S.P. and B.S. Fox, Tissue engineering of bone. Cell based 
strategies. Clin Orthop Relat Res, 1999(367 Suppl): p. S68-83. 
179. Whang, K., et al., Ectopic bone formation via rhBMP-2 delivery from 
porous bioabsorbable polymer scaffolds. J Biomed Mater Res, 1998. 
42(4): p. 491-9. 
180. Lanza, R.P., et al., Xenotransplantation of cells using biodegradable 
microcapsules. Transplantation, 1999. 67(8): p. 1105-11. 
181. Perka, C., et al., Matrix-mixed culture: new methodology for chondrocyte 
culture and preparation of cartilage transplants. J Biomed Mater Res, 
2000. 49(3): p. 305-11. 
182. Griffith, L.G., Emerging design principles in biomaterials and scaffolds for 
tissue engineering. Ann N Y Acad Sci, 2002. 961: p. 83-95. 
References 
 
84 
 
183. Kim, H.W. and C.D. Han, An overview of cartilage tissue engineering. 
Yonsei Med J, 2000. 41(6): p. 766-73. 
184. Kim, B.S. and D.J. Mooney, Development of biocompatible synthetic 
extracellular matrices for tissue engineering. Trends Biotechnol, 1998. 
16(5): p. 224-30. 
185. Ramaswamy, S., et al., An analysis of the integration between articular 
cartilage and nondegradable hydrogel using magnetic resonance imaging. 
J Biomed Mater Res B Appl Biomater, 2006. 77(1): p. 144-8. 
186. Bruining, M.J., et al., Biodegradable three-dimensional networks of 
poly(dimethylamino ethyl methacrylate). Synthesis, characterization and in 
vitro studies of structural degradation and cytotoxicity. Biomaterials, 2000. 
21(6): p. 595-604. 
187. Li, S.M., H. Garreau, and M. Vert, Structure-property relationships in the 
case of the degradation of massive poly(α-hydroxy acids) in aquous 
media. Part 1: poly(DL-lactic acid). J Mater Sci Mater Med 1990. 1: p. 123-
130. 
188. Germain, L., et al., Engineering human tissues for in vivo applications. Ann 
N Y Acad Sci, 2002. 961: p. 268-70. 
189. Vacanti, J.P., et al., Transplantation of cells in matrices for tissue 
regeneration. Adv Drug Deliv Rev, 1998. 33(1-2): p. 165-182. 
190. Thomson, J.A., et al., Embryonic stem cell lines derived from human 
blastocysts. Science, 1998. 282(5391): p. 1145-7. 
191. Koechlin, N., et al., Conversion of a rabbit proximal convoluted tubule 
(PCT) into a cell monolayer: ultrastructural study of cell dedifferentiation 
and redifferentiation. Eur J Cell Biol, 1991. 54(2): p. 224-36. 
192. Minuth, W.W., M. Sittinger, and S. Kloth, Tissue engineering: generation of 
differentiated artificial tissues for biomedical applications. Cell Tissue Res, 
1998. 291(1): p. 1-11. 
193. Butor, C. and J. Davoust, Apical to basolateral surface area ratio and 
polarity of MDCK cells grown on different supports. Exp Cell Res, 1992. 
203(1): p. 115-27. 
194. Walsh-Reitz, M.M., H.N. Aithal, and F.G. Toback, Na regulates growth of 
kidney epithelial cells induced by lowering extracellular K concentration. 
Am J Physiol, 1984. 247(5 Pt 1): p. C321-6. 
References 
 
85 
 
195. Sikavitsas, V.I., G.N. Bancroft, and A.G. Mikos, Formation of three-
dimensional cell/polymer constructs for bone tissue engineering in a 
spinner flask and a rotating wall vessel bioreactor. J Biomed Mater Res, 
2002. 62(1): p. 136-48. 
196. Sittinger, M., et al., Tissue engineering and autologous transplant 
formation: practical approaches with resorbable biomaterials and new cell 
culture techniques. Biomaterials, 1996. 17(3): p. 237-42. 
197. Colton, C.K., Implantable biohybrid artificial organs. Cell Transplant, 1995. 
4(4): p. 415-36. 
198. Palermo, A.T., et al., Bone marrow contribution to skeletal muscle: a 
physiological response to stress. Dev Biol, 2005. 279(2): p. 336-44. 
199. Metheny-Barlow, L.J., et al., Direct chemotactic action of angiopoietin-1 on 
mesenchymal cells in the presence of VEGF. Microvasc Res, 2004. 68(3): 
p. 221-30. 
200. Otto, W.R. and J. Rao, Tomorrow's skeleton staff: mesenchymal stem 
cells and the repair of bone and cartilage. Cell Prolif, 2004. 37(1): p. 97-
110. 
201. Friedenstein, A.J., R.K. Chailakhjan, and K.S. Lalykina, The development 
of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and 
spleen cells. Cell Tissue Kinet, 1970. 3(4): p. 393-403. 
202. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal 
stem cells. Science, 1999. 284(5411): p. 143-7. 
203. Kakudo, N., A. Shimotsuma, and K. Kusumoto, Fibroblast growth factor-2 
stimulates adipogenic differentiation of human adipose-derived stem cells. 
Biochem Biophys Res Commun, 2007. 359(2): p. 239-44. 
204. Zuk, P.A., et al., Human adipose tissue is a source of multipotent stem 
cells. Mol Biol Cell, 2002. 13(12): p. 4279-95. 
205. De Girolamo, L., et al., Stemness and osteogenic and adipogenic potential 
are differently impaired in subcutaneous and visceral adipose derived 
stem cells (ASCs) isolated from obese donors. Int J Immunopathol 
Pharmacol, 2013. 26(1 Suppl): p. 11-21. 
206. Rada, T., et al., Chondrogenic potential of two hASCs subpopulations 
loaded onto gellan gum hydrogel evaluated in a nude mice model. Curr 
Stem Cell Res Ther, 2013. 8(5): p. 357-64. 
References 
 
86 
 
207. Nishida, M., et al., Improvement of cardiac function by bone marrow cell 
implantation in a rat hypoperfusion heart model. Ann Thorac Surg, 2003. 
75(3): p. 768-73; discussion 773-4. 
208. Safford, K.M., et al., Neurogenic differentiation of murine and human 
adipose-derived stromal cells. Biochem Biophys Res Commun, 2002. 
294(2): p. 371-9. 
209. Philips, B.J., K.G. Marra, and J.P. Rubin, Healing of grafted adipose 
tissue: current clinical applications of adipose-derived stem cells for breast 
and face reconstruction. Wound Repair Regen, 2014. 22 Suppl 1: p. 11-3. 
210. de Girolamo, L., et al., Role of autologous rabbit adipose-derived stem 
cells in the early phases of the repairing process of critical bone defects. J 
Orthop Res, 2011. 29(1): p. 100-8. 
211. Tullberg-Reinert, H. and G. Jundt, In situ measurement of collagen 
synthesis by human bone cells with a sirius red-based colorimetric 
microassay: effects of transforming growth factor beta2 and ascorbic acid 
2-phosphate. Histochem Cell Biol, 1999. 112(4): p. 271-6. 
212. Halvorsen, Y.D., et al., Extracellular matrix mineralization and osteoblast 
gene expression by human adipose tissue-derived stromal cells. Tissue 
Eng, 2001. 7(6): p. 729-41. 
213. de Girolamo, L., et al., Human adipose-derived stem cells isolated from 
young and elderly women: their differentiation potential and scaffold 
interaction during in vitro osteoblastic differentiation. Cytotherapy, 2009. 
11(6): p. 793-803. 
214. Farndale, R.W., D.J. Buttle, and A.J. Barrett, Improved quantitation and 
discrimination of sulphated glycosaminoglycans by use of 
dimethylmethylene blue. Biochim Biophys Acta, 1986. 883(2): p. 173-7. 
215. Wolf, F., et al., Cartilage tissue engineering using pre-aggregated human 
articular chondrocytes. Eur Cell Mater, 2008. 16: p. 92-9. 
216. Lynch, S.E., R.J. Genco, and R.E. Marx, Tissue engineering: applications 
in maxillofacial surgery and periodontics. Surrey: quintessence publishing 
co, 1999. 
217. Marx, R.E., Platelet-rich plasma: evidence to support its use. J Oral 
Maxillofac Surg, 2004. 62(4): p. 489-96. 
References 
 
87 
 
218. Mundy, G.R., et al., The effects of cytokines and growth factors on 
osteoblastic cells. Bone, 1995. 17(2 Suppl): p. 71S-75S. 
219. Mundy, G.R., Regulation of bone formation by bone morphogenetic 
proteins and other growth factors. Clin Orthop Relat Res, 1996(324): p. 
24-8. 
220. Eppley, B.L., J.E. Woodell, and J. Higgins, Platelet quantification and 
growth factor analysis from platelet-rich plasma: implications for wound 
healing. Plast Reconstr Surg, 2004. 114(6): p. 1502-8. 
221. Chaussain Miller, C., et al., Human dermal and gingival fibroblasts in a 
three-dimensional culture: a comparative study on matrix remodeling. Clin 
Oral Investig, 2002. 6(1): p. 39-50. 
222. Toyserkani, N.M., et al., Adipose-Derived Stem Cells: New Treatment for 
Wound Healing? Ann Plast Surg, 2015. 75(1): p. 117-23. 
223. Broccaioli, E., et al., Mesenchymal Stem Cells from Bichat's Fat Pad: In 
Vitro Comparison with Adipose-Derived Stem Cells from Subcutaneous 
Tissue. Biores Open Access, 2013. 2(2): p. 107-17. 
224. Chen, Y., et al., Improvement in the repair of defects in maxillofacial soft 
tissue in irradiated minipigs by a mixture of adipose-derived stem cells and 
platelet-rich fibrin. Br J Oral Maxillofac Surg, 2014. 52(8): p. 740-5. 
225. Kawase, T., et al., Platelet-rich plasma provides nucleus for mineralization 
in cultures of partially differentiated periodontal ligament cells. In Vitro Cell 
Dev Biol Anim, 2005. 41(5-6): p. 171-6. 
226. Goto, H., et al., Platelet-rich plasma/osteoblasts complex induces bone 
formation via osteoblastic differentiation following subcutaneous 
transplantation. J Periodontal Res, 2006. 41(5): p. 455-62. 
227. He, L., et al., A comparative study of platelet-rich fibrin (PRF) and platelet-
rich plasma (PRP) on the effect of proliferation and differentiation of rat 
osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 
2009. 108(5): p. 707-13. 
228. Kanno, T., et al., Platelet-rich plasma enhances human osteoblast-like cell 
proliferation and differentiation. J Oral Maxillofac Surg, 2005. 63(3): p. 
362-9. 
229. Celotti, F., et al., Effect of platelet-rich plasma on migration and 
proliferation of SaOS-2 osteoblasts: role of platelet-derived growth factor 
References 
 
88 
 
and transforming growth factor-beta. Wound Repair Regen, 2006. 14(2): 
p. 195-202. 
230. Ogino, Y., et al., The contribution of platelet-derived growth factor, 
transforming growth factor-beta1, and insulin-like growth factor-I in 
platelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod, 2006. 101(6): p. 724-9. 
231. Cenni, E., et al., Effects of activated platelet concentrates on human 
primary cultures of fibroblasts and osteoblasts. J Periodontol, 2005. 76(3): 
p. 323-8. 
232. Graziani, F., et al., The in vitro effect of different PRP concentrations on 
osteoblasts and fibroblasts. Clin Oral Implants Res, 2006. 17(2): p. 212-9. 
233. Hsu, C.W., K. Yuan, and C.C. Tseng, The negative effect of platelet-rich 
plasma on the growth of human cells is associated with secreted 
thrombospondin-1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 
2009. 107(2): p. 185-92. 
234. Lind, M., Growth factor stimulation of bone healing. Effects on osteoblasts, 
osteomies, and implants fixation. Acta Orthop Scand Suppl, 1998. 283: p. 
2-37. 
235. Pessoa, R.S., et al., Effects of platelet-rich plasma on healing of alveolar 
socket: split-mouth histological and histometric evaluation in Cebus apella 
monkeys. Indian J Dent Res, 2009. 20(4): p. 442-7. 
236. Hatakeyama, M., et al., Radiographic and histomorphometric analysis of 
bone healing using autogenous graft associated with platelet-rich plasma 
obtained by 2 different methods. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod, 2008. 105(1): p. e13-8. 
237. Garcia, R.V., et al., Effect of platelet-rich plasma on peri-implant bone 
repair: a histologic study in dogs. J Oral Implantol, 2010. 36(4): p. 281-90. 
238. Jeong, S.M., et al., Simultaneous sinus lift and implantation using platelet-
rich fibrin as sole grafting material. J Craniomaxillofac Surg, 2014. 42(6): 
p. 990-4. 
239. Nkenke, E., et al., Morbidity of harvesting of chin grafts: a prospective 
study. Clin Oral Implants Res, 2001. 12(5): p. 495-502. 
References 
 
89 
 
240. Kassolis, J.D., P.S. Rosen, and M.A. Reynolds, Alveolar ridge and sinus 
augmentation utilizing platelet-rich plasma in combination with freeze-dried 
bone allograft: case series. J Periodontol, 2000. 71(10): p. 1654-61. 
241. Kim, S.G., et al., Use of particulate dentin-plaster of Paris combination 
with/without platelet-rich plasma in the treatment of bone defects around 
implants. Int J Oral Maxillofac Implants, 2002. 17(1): p. 86-94. 
242. Schlegel, A.K., [Bio-Oss bone replacement material. Long-term results 
with Bio-Oss bone replacement material]. Schweiz Monatsschr Zahnmed, 
1996. 106(2): p. 141-9. 
243. Schlegel, A.K. and K. Donath, BIO-OSS--a resorbable bone substitute? J 
Long Term Eff Med Implants, 1998. 8(3-4): p. 201-9. 
244. Accorsi-Mendonca, T., et al., Physicochemical characterization of two 
deproteinized bovine xenografts. Braz Oral Res, 2008. 22(1): p. 5-10. 
245. Berglundh, T. and J. Lindhe, Healing around implants placed in bone 
defects treated with Bio-Oss. An experimental study in the dog. Clin Oral 
Implants Res, 1997. 8(2): p. 117-24. 
246. Donos, N., et al., Bone formation by enamel matrix proteins and 
xenografts: an experimental study in the rat ramus. Clin Oral Implants 
Res, 2005. 16(2): p. 140-6. 
247. Shayesteh, Y.S., et al., Evaluation of platelet-rich plasma in combination 
with deproteinized bovine bone mineral in the rabbit cranium. Perio 2006. 
4(3): p. 1-9. 
248. Paknejad, M., et al., Evaluation of the Effect of Plasma Rich in Growth 
Factors (PRGF) on Bone Regeneration. J Dent (Tehran), 2012. 9(1): p. 
59-67. 
249. Aghaloo, T.L., P.K. Moy, and E.G. Freymiller, Investigation of platelet-rich 
plasma in rabbit cranial defects: A pilot study. J Oral Maxillofac Surg, 
2002. 60(10): p. 1176-81. 
250. Wiltfang, J., et al., Sinus floor augmentation with beta-tricalciumphosphate 
(beta-TCP): does platelet-rich plasma promote its osseous integration and 
degradation? Clin Oral Implants Res, 2003. 14(2): p. 213-8. 
251. Slater, M., et al., Involvement of platelets in stimulating osteogenic activity. 
J Orthop Res, 1995. 13(5): p. 655-63. 
References 
 
90 
 
252. Caceres, M., et al., Effect of platelet-rich plasma on cell adhesion, cell 
migration, and myofibroblastic differentiation in human gingival fibroblasts. 
J Periodontol, 2008. 79(4): p. 714-20. 
253. Roffi, A., et al., Does platelet-rich plasma freeze-thawing influence growth 
factor release and their effects on chondrocytes and synoviocytes? 
Biomed Res Int, 2014. 2014: p. 692913. 
254. Kon, E., et al., PRP for the treatment of cartilage pathology. Open Orthop 
J, 2013. 7: p. 120-8. 
255. Zimmermann, R., et al., Sample preparation technique and white cell 
content influence the detectable levels of growth factors in platelet 
concentrates. Vox Sang, 2003. 85(4): p. 283-9. 
256. Perut, F., et al., Preparation method and growth factor content of platelet 
concentrate influence the osteogenic differentiation of bone marrow 
stromal cells. Cytotherapy, 2013. 15(7): p. 830-9. 
257. Anitua, E., et al., Biological Stability of Plasma Rich in Growth Factors Eye 
Drops After Storage of 3 Months. Cornea, 2013. 32(10): p. 1380-6. 
258. Weibrich, G., et al., Growth factor levels in platelet-rich plasma and 
correlations with donor age, sex, and platelet count. J Craniomaxillofac 
Surg, 2002. 30(2): p. 97-102. 
259. Kilian, O., et al., Effects of platelet growth factors on human mesenchymal 
stem cells and human endothelial cells in vitro. Eur J Med Res, 2004. 9(7): 
p. 337-44. 
260. Clausen, C., et al., Homologous activated platelets stimulate differentiation 
and proliferation of primary human bone cells. Cells Tissues Organs, 
2006. 184(2): p. 68-75. 
261. Arpornmaeklong, P., et al., Influence of platelet-rich plasma (PRP) on 
osteogenic differentiation of rat bone marrow stromal cells. An in vitro 
study. Int J Oral Maxillofac Surg, 2004. 33(1): p. 60-70. 
262. Gruber, R., et al., Platelet-released supernatants increase migration and 
proliferation, and decrease osteogenic differentiation of bone marrow-
derived mesenchymal progenitor cells under in vitro conditions. Platelets, 
2004. 15(1): p. 29-35. 
References 
 
91 
 
263. Choi, B.H., et al., Effect of platelet-rich plasma (PRP) concentration on the 
viability and proliferation of alveolar bone cells: an in vitro study. Int J Oral 
Maxillofac Surg, 2005. 34(4): p. 420-4. 
264. Zimmermann, R., et al., Different preparation methods to obtain platelet 
components as a source of growth factors for local application. 
Transfusion, 2001. 41(10): p. 1217-24. 
265. Sundman, E.A., B.J. Cole, and L.A. Fortier, Growth factor and catabolic 
cytokine concentrations are influenced by the cellular composition of 
platelet-rich plasma. Am J Sports Med, 2011. 39(10): p. 2135-40. 
266. Liu, Y., et al., Fibroblast proliferation due to exposure to a platelet 
concentrate in vitro is pH dependent. Wound Repair Regen, 2002. 10(5): 
p. 336-40. 
267. Anitua, E., et al., The potential impact of the preparation rich in growth 
factors (PRGF) in different medical fields. Biomaterials, 2007. 28(31): p. 
4551-60. 
268. Iqbal, J., S.H. Pepkowitz, and E. Klapper, Platelet-rich plasma for the 
replenishment of bone. Curr Osteoporos Rep, 2011. 9(4): p. 258-63. 
269. Lucarelli, E., et al., Platelet-derived growth factors enhance proliferation of 
human stromal stem cells. Biomaterials, 2003. 24(18): p. 3095-100. 
270. Burkhart, J.M., et al., The first comprehensive and quantitative analysis of 
human platelet protein composition allows the comparative analysis of 
structural and functional pathways. Blood, 2012. 120(15): p. e73-82. 
271. Del Fabbro, M., et al., Autologous platelet concentrate for post-extraction 
socket healing: a systematic review. Eur J Oral Implantol, 2014. 7(4): p. 
333-44. 
 
